Diabetes & Metabolism Journal

Short Communication

Drug/Regimen
The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-World Data Study: Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek; Diabetes Metab J. 2023;47(1):135-139. Published online April 29, 2022; DOI: https://doi.org/10.4093/dmj.2021.0373

7,520 View
296 Download

Abstract PDF Supplementary Material PubReader ePub: We compared the glycemic efficacy of treatment intensification between quadruple oral antidiabetic drug therapy and once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA)-based triple therapy in patients with poorly controlled type 2 diabetes mellitus refractory to triple oral therapy. For 24 weeks, changes in glycosylated hemoglobin (HbA1c) from baseline were compared between the two treatment groups. Of all 96 patients, 50 patients were treated with quadruple therapy, and 46 were treated with GLP-1RA therapy. Reductions in HbA1c for 24 weeks were comparable (in both, 1.1% reduction from baseline; P=0.59). Meanwhile, lower C-peptide level was associated with a lower glucose-lowering response of GLP-1RA therapy (R=0.3, P=0.04) but not with quadruple therapy (R=–0.13, P=0.40). HbA1c reduction by GLP-1RA therapy was inferior to that by quadruple therapy in the low C-peptide subgroup (mean, –0.1% vs. –1.3%; P=0.04). Treatment intensification by switching to quadruple oral therapy showed similar glucose-lowering efficacy to weekly GLP-1RA-based triple therapy. Meanwhile, the therapeutic response was affected by C-peptide levels in the GLP-1RA therapy group but not in the quadruple therapy group.

Original Article

Type 1 Diabetes
Abnormal Responses in Cognitive Impulsivity Circuits Are Associated with Glycosylated Hemoglobin Trajectories in Type 1 Diabetes Mellitus and Impaired Metabolic Control: Helena Jorge, Isabel C. Duarte, Sandra Paiva, Ana Paula Relvas, Miguel Castelo-Branco; Diabetes Metab J. 2022;46(6):866-878. Published online March 22, 2022; DOI: https://doi.org/10.4093/dmj.2021.0307

4,401 View
173 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Risky health decisions and impulse control profiles may impact on metabolic control in type 1 diabetes mellitus (T1DM). We hypothesize that the neural correlates of cognitive impulsivity and decision-making in T1DM relate to metabolic control trajectories.
Methods
We combined functional magnetic resonance imaging (fMRI), measures of metabolic trajectories (glycosylated hemoglobin [HbA1c] over multiple time points) and behavioral assessment using a cognitive impulsivity paradigm, the Balloon Analogue Risk Task (BART), in 50 participants (25 T1DM and 25 controls).
Results
Behavioral results showed that T1DM participants followed a rigid conservative risk strategy along the iterative game. Imaging group comparisons showed that patients showed larger activation of reward related, limbic regions (nucleus accumbens, amygdala) and insula (interoceptive saliency network) in initial game stages. Upon game completion differences emerged in relation to error monitoring (anterior cingulate cortex [ACC]) and inhibitory control (inferior frontal gyrus). Importantly, activity in the saliency network (ACC and insula), which monitors interoceptive states, was related with metabolic trajectories, which was also found for limbic/reward networks. Parietal and posterior cingulate regions activated both in controls and patients with adaptive decision-making, and positively associated with metabolic trajectories.
Conclusion
We found triple converging evidence when comparing metabolic trajectories, patients versus controls or risk averse (non-learners) versus patients who learned by trial and error. Dopaminergic reward and saliency (interoceptive and error monitoring) circuits show a tight link with impaired metabolic trajectories and cognitive impulsivity in T1DM. Activity in parietal and posterior cingulate are associated with adaptive trajectories. This link between reward-saliency-inhibition circuits suggests novel strategies for patient management.

Citations

Citations to this article as recorded by

The usefulness of an intervention with a serious video game as a complementary approach to cognitive behavioural therapy in eating disorders: A pilot randomized clinical trial for impulsivity management
Cristina Vintró‐Alcaraz, Núria Mallorquí‐Bagué, María Lozano‐Madrid, Giulia Testa, Roser Granero, Isabel Sánchez, Janet Treasure, Susana Jiménez‐Murcia, Fernando Fernández‐Aranda
European Eating Disorders Review.2023; 31(6): 781. CrossRef
Adaptations of the balloon analog risk task for neuroimaging settings: a systematic review
Charline Compagne, Juliana Teti Mayer, Damien Gabriel, Alexandre Comte, Eloi Magnin, Djamila Bennabi, Thomas Tannou
Frontiers in Neuroscience.2023;[Epub] CrossRef
Trust-based health decision-making recruits the neural interoceptive saliency network which relates to temporal trajectories of Hemoglobin A1C in Diabetes Type 1
Helena Jorge, Isabel C. Duarte, Miguel Melo, Ana Paula Relvas, Miguel Castelo-Branco
Brain Imaging and Behavior.2023; 18(1): 171. CrossRef

Short Communication

Type 1 Diabetes
Real-World Analysis of Therapeutic Outcome in Type 1 Diabetes Mellitus at a Tertiary Care Center: Antonia Kietaibl, Michaela Riedl, Latife Bozkurt; Diabetes Metab J. 2022;46(1):149-153. Published online July 6, 2021; DOI: https://doi.org/10.4093/dmj.2020.0267

4,355 View
144 Download

Abstract PDF PubReader ePub: Insulin replacement in type 1 diabetes mellitus (T1DM) needs intensified treatment, which can either be performed by multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). This retrospective analysis of a real-world scenario aimed to evaluate whether glycaemic and cardiovascular risk factors could be controlled with CSII outclass MDI as suggested by recent evidence. Data from patients with either insulin pump (n=68) or injection (n=224) therapy at an Austrian tertiary care centre were analysed between January 2016 and December 2017. There were no significant differences with regard to the latest glycosylated hemoglobin, cardiovascular risk factor control or diabetes-associated late complications. Hypoglycaemia was less frequent (P<0.001), sensor-augmented therapy was more common (P=0.003) and mean body mass index (BMI) was higher (P=0.002) with CSII treatment. This retrospective analysis of real-world data in T1DM did not demonstrate the superiority of insulin pump treatment with regard to glycaemic control or cardiovascular risk factor control.

Review

Cardiovascular Risk/Epidemiology
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes: Jin Joo Park; Diabetes Metab J. 2021;45(2):146-157. Published online March 25, 2021; DOI: https://doi.org/10.4093/dmj.2020.0282; Correction in: Diabetes Metab J 2021;45(5):796

13,747 View
1,205 Download
51 Web of Science
54 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients with DM have a worse prognosis than those without DM. Diabetes can cause myocardial ischemia via micro- and macrovasculopathy and can directly exert deleterious effects on the myocardium. Hyperglycemia, hyperinsulinemia, and insulin resistance can cause alterations in vascular homeostasis. Then, reduced nitric oxide and increased reactive oxygen species levels favor inflammation leading to atherothrombotic progression and myocardial dysfunction. The classification, diagnosis, and treatment of HF for a patient with and without DM remain the same. Until now, drugs targeting neurohumoral and metabolic pathways improved mortality and morbidity in HF with reduced ejection fraction (HFrEF). Therefore, all HFrEF patients should receive guideline-directed medical therapy. By contrast, drugs modulating neurohumoral activity did not improve survival in HF with preserved ejection fraction (HFpEF) patients. Trials investigating whether sodium-glucose cotransporter-2 inhibitors are effective in HFpEF are on-going. This review will summarize the epidemiology, pathophysiology, and treatment of HF in diabetes.

Citations

Citations to this article as recorded by

Efficacy of Platelet-Rich Plasma in the Treatment of Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis
Yundong Peng, JiePing Wang, Xinyao Liu, Yanqing Zhou, Shaohui Jia, Jinrong Xu, Cheng Zheng
Annals of Vascular Surgery.2024; 98: 365. CrossRef
Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts
Ashot Avagimyan, Federica Fogacci, Nana Pogosova, Lev Kakrurskiy, Eugenia Kogan, Olga Urazova, Zhanna Kobalava, Liudmila Mikhaleva, Rositsa Vandysheva, Gioeva Zarina, Artem Trofimenko, Grizelda Navasardyan, Lusine Mkrtchyan, Mattia Galli, Zinaida Jndoyan,
Current Problems in Cardiology.2024; 49(1): 102052. CrossRef
Emerging Biomarkers in the Laboratory and in Practice: A Novel Approach to Diagnosing Heart Failure in Diabetes
Rachel E. Aaron, Tiffany Tian, G. Alexander Fleming, David B. Sacks, James L. Januzzi, Rodica Pop-Busui, Ibrahim A. Hashim, Alan H. B. Wu, Ambarish Pandey, David C. Klonoff
Journal of Diabetes Science and Technology.2024;[Epub] CrossRef
Research Progress on the Relationship between HbA_1c and Diabetes Complicated with Chronic Heart Failure
·依沙迪达尔
Advances in Clinical Medicine.2024; 14(01): 1117. CrossRef
Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure
Ya-Wen Lin, Chun-Hsiang Lin, Cheng-Li Lin, Che-Huei Lin, Ming-Hung Lin
Journal of Cardiovascular Pharmacology and Therapeutics.2024;[Epub] CrossRef
The Role of Epicardial Adipose Tissue in Acute Coronary Syndromes, Post-Infarct Remodeling and Cardiac Regeneration
Kamil Krauz, Marcel Kempiński, Paweł Jańczak, Karol Momot, Maciej Zarębiński, Izabela Poprawa, Małgorzata Wojciechowska
International Journal of Molecular Sciences.2024; 25(7): 3583. CrossRef
Molecular mechanisms of metabolic dysregulation in diabetic cardiomyopathy
Yue Zeng, Yilang Li, Wenyue Jiang, Ning Hou
Frontiers in Cardiovascular Medicine.2024;[Epub] CrossRef
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,496 adults using serial echocardiography
Gyuri Kim, Tae Yang Yu, Jae Hwan Jee, Ji Cheol Bae, Mira Kang, Jae Hyeon Kim
Diabetes & Metabolism.2024; : 101534. CrossRef
SGLT2 Inhibitors in the Cardiovascular Disease
Jin Joo Park
The Journal of Korean Diabetes.2024; 25(1): 26. CrossRef
Metabolic Alteration Bridging the Prediabetic State and Colorectal Cancer
Antonino Colloca, Isabella Donisi, Camilla Anastasio, Maria Luisa Balestrieri, Nunzia D’Onofrio
Cells.2024; 13(8): 663. CrossRef
Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions
Lu Zhao, Haoran Hu, Lin Zhang, Zheting Liu, Yunchao Huang, Qian Liu, Liang Jin, Meifei Zhu, Ling Zhang
MedComm.2024;[Epub] CrossRef
Methods to predict heart failure in diabetes patients
Alexander E. Berezin, Tetiana A Berezina, Uta C. Hoppe, Michael Lichtenauer, Alexander A. Berezin
Expert Review of Endocrinology & Metabolism.2024; : 1. CrossRef
Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure
Andrew Xanthopoulos, Nikolaos Katsiadas, Spyridon Skoularigkis, Dimitrios E. Magouliotis, Niki Skopeliti, Sotirios Patsilinakos, Alexandros Briasoulis, Filippos Triposkiadis, John Skoularigis
Life.2023; 13(8): 1778. CrossRef
Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism
Bo Liang, Rui Li, Peng Zhang, Ning Gu
Journal of Cardiovascular Translational Research.2023; 16(2): 327. CrossRef
Causes and Determinants of Heart Failure Readmissions Post Transcutaneous Aortic Valve Replacement: A Systematic Review and Meta-Analysis
Farah Yasmin, Muhammad Aamir, Abdul Moeed, Kinza Iqbal, Aymen Iqbal, Muhammad Sohaib Asghar, Waqas Ullah, Indranee Rajapreyar, Yevgeniy Brailovsky
Current Problems in Cardiology.2023; 48(1): 101428. CrossRef
Discussion of a study on the role of EMS in prognosis of elderly patients with AHF
Qingzhuo Yang, Hui Wu, Di Liu, Yunzhao Li, Gang Zhou, Dong Zhang, Yanfang Liu, Yi Li
International Journal of Cardiology.2023; 377: 91. CrossRef
The management correlation between metabolic index, cardiovascular health, and diabetes combined with cardiovascular disease
Yi Zhang, Chao Liu, Yijing Xu, Yanlei Wang, Fang Dai, Honglin Hu, Tian Jiang, Yunxia Lu, Qiu Zhang
Frontiers in Endocrinology.2023;[Epub] CrossRef
Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
International Journal of Heart Failure.2023; 5(1): 1. CrossRef
Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 10. CrossRef
Lower Circulating Cell-Free Mitochondrial DNA Is Associated with Heart Failure in Type 2 Diabetes Mellitus Patients
Tetiana A. Berezina, Mykola P. Kopytsya, Olga V. Petyunina, Alexander A. Berezin, Zeljko Obradovic, Lukas Schmidbauer, Michael Lichtenauer, Alexander E. Berezin
Cardiogenetics.2023; 13(1): 15. CrossRef
Novel model predicts diastolic cardiac dysfunction in type 2 diabetes
Mingyu Hao, Xiaohong Huang, Xueting Liu, Xiaokang Fang, Haiyan Li, Lingbo Lv, Liming Zhou, Tiecheng Guo, Dewen Yan
Annals of Medicine.2023; 55(1): 766. CrossRef
Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK/Egr‐1 pathway
Qing Wu, Ming Zhao, Dongling Li, Xi He, Weijin Zang
The FASEB Journal.2023;[Epub] CrossRef
Ferroptosis: roles and molecular mechanisms in diabetic cardiomyopathy
Yangting Zhao, Binjing Pan, Xiaoyu Lv, Chongyang Chen, Kai Li, Yawen Wang, Jingfang Liu
Frontiers in Endocrinology.2023;[Epub] CrossRef
Cardiorenal syndrome and diabetes: an evil pairing
Ana Belén Méndez Fernández, Ander Vergara Arana, Aleix Olivella San Emeterio, Maria Antonieta Azancot Rivero, Toni Soriano Colome, Maria Jose Soler Romeo
Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef
Therapeutic Potential of Hibiscus sabdariffa Linn. in Attenuating Cardiovascular Risk Factors
Syaifuzah Sapian, Asma Ali Ibrahim Mze, Fatin Farhana Jubaidi, Nor Anizah Mohd Nor, Izatus Shima Taib, Zariyantey Abd Hamid, Satirah Zainalabidin, Nur Najmi Mohamad Anuar, Haliza Katas, Jalifah Latip, Juriyati Jalil, Nur Faizah Abu Bakar, Siti Balkis Budi
Pharmaceuticals.2023; 16(6): 807. CrossRef
Exploring the prospect of intrinsic wave propagation in evaluating myocardial stiffness among patients with type 2 diabetes
Qiao Cheng, Xiao Huang, Xinying Fan, Jie Sun, Jun Zhang, Qiaoying Tang, Youbin Deng, Xiaojun Bi
Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef
The multidimensional prognostic index (MPI) predicts long-term mortality in old type 2 diabetes mellitus patients: a 13-year follow-up study
F. Salis, E. Cossu, A. Mandas
Journal of Endocrinological Investigation.2023; 47(1): 191. CrossRef
PRDM16 exerts critical role in myocardial metabolism and energetics in type 2 diabetes induced cardiomyopathy
Tongtong Hu, Qingqing Wu, Qi Yao, Jiabin Yu, Kebing Jiang, Ying Wan, Qizhu Tang
Metabolism.2023; 146: 155658. CrossRef
Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
Michael Gotzmann, Pauline Henk, Ulrik Stervbo, Arturo Blázquez-Navarro, Andreas Mügge, Nina Babel, Timm H. Westhoff
Journal of Clinical Medicine.2023; 12(13): 4458. CrossRef
Features of the course and complications of acute myocardial infarction in type 2 diabetes mellitus
M. N. Zatsepina, F. O. Ushanova, T. L. Bogacheva
FOCUS. Endocrinology.2023; 4(2): 42. CrossRef
Admission triglyceride-glucose index is predictor of long-term mortality and appropriate implantable cardiac defibrillator therapy in patients with heart failure
Kazım S Özcan, Mert İ Hayıroğlu, Tufan Çınar
Biomarkers in Medicine.2023; 17(10): 487. CrossRef
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders
Antonietta Fazio, Camilla Evangelisti, Alessandra Cappellini, Sara Mongiorgi, Foteini-Dionysia Koufi, Irene Neri, Maria Vittoria Marvi, Michele Russo, Alessandra Ghigo, Lucia Manzoli, Roberta Fiume, Stefano Ratti
International Journal of Molecular Sciences.2023; 24(17): 13096. CrossRef
Research progress of dihydromyricetin in the treatment of diabetes mellitus
Ziyuan Wang, Zhuoran Cao, Zhiying Yue, Zhengfeng Yang
Frontiers in Endocrinology.2023;[Epub] CrossRef
Assessment of subclinical left ventricular myocardial systolic dysfunction in type 2 diabetes mellitus patients with or without hypertension by global and segmental myocardial work
Guang-An Li, Jun Huang, Xiao Sheng, Li Fan
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Managing heart failure in diabetics with dual acting sotagliflozin—A review
Kushal Seni, Pooja A Chawla
Health Sciences Review.2023; 9: 100130. CrossRef
Association between triglyceride glucose-body mass index and heart failure in subjects with diabetes mellitus or prediabetes mellitus: a cross-sectional study
Shuping Yang, Xiangxiang Shi, Wanlu Liu, Zhaokai Wang, Ruoshui Li, Xianzhi Xu, Chaofan Wang, Lei Li, Ruili Wang, Tongda Xu
Frontiers in Endocrinology.2023;[Epub] CrossRef
Influence of Sociodemographic Variables and Healthy Habits on the Values of Insulin Resistance Indicators in 386,924 Spanish Workers
Miguel Mestre Font, Carla Busquets-Cortés, José Ignacio Ramírez-Manent, Pilar Tomás-Gil, Hernán Paublini, Ángel Arturo López-González
Nutrients.2023; 15(24): 5122. CrossRef
The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors
Theocharis Koufakis, George Giannakoulas, Pantelis Zebekakis, Kalliopi Kotsa
Expert Opinion on Pharmacotherapy.2022; 23(3): 321. CrossRef
The peculiar role of vitamin D in the pathophysiology of cardiovascular and neurodegenerative diseases
Milijana Janjusevic, Giulia Gagno, Alessandra Lucia Fluca, Laura Padoan, Antonio Paolo Beltrami, Gianfranco Sinagra, Rita Moretti, Aneta Aleksova
Life Sciences.2022; 289: 120193. CrossRef
Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants
Francesca Romana Prandi, Isabella Evangelista, Domenico Sergi, Alberto Palazzuoli, Francesco Romeo
Heart Failure Reviews.2022; 28(3): 597. CrossRef
Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus
Yu. G. Gorb, S. A. Serik, O. V. Tkachenko, V. V. Ryabukha
Ukraïnsʹkij žurnal medicini, bìologìï ta sportu.2022; 7(1): 14. CrossRef
Metabonomic Characteristics of Myocardial Diastolic Dysfunction in Type 2 Diabetic Cardiomyopathy Patients
Mingyu Hao, Jianxin Deng, Xiaohong Huang, Haiyan Li, Huiting Ou, Xiangsheng Cai, Jiajie She, Xueting Liu, Ling Chen, Shujuan Chen, Wenlan Liu, Dewen Yan
Frontiers in Physiology.2022;[Epub] CrossRef
Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus
Alexander A. Berezin, Michael Lichtenauer, Elke Boxhammer, Ivan M. Fushtey, Alexander E. Berezin
Frontiers in Physiology.2022;[Epub] CrossRef
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
Rodica Pop-Busui, James L. Januzzi, Dennis Bruemmer, Sonia Butalia, Jennifer B. Green, William B. Horton, Colette Knight, Moshe Levi, Neda Rasouli, Caroline R. Richardson
Diabetes Care.2022; 45(7): 1670. CrossRef
Von Willebrand factor (vWF) in patients with heart failure with preserved ejection fraction (HFpEF): A retrospective observational study
Mayila Abudoukelimu, Bayinsilema Ba, Yan Kai Guo, Jie Xu
Medicine.2022; 101(31): e29854. CrossRef
Why Does the Intravenous Iron Supplementation Not Work in Heart Failure Patients on Hemodialysis?
Jin Joo Park
CardioMetabolic Syndrome Journal.2022; 2(2): 176. CrossRef
Severe hypoglycemia and risk of hospitalization for heart failure in adults with diabetes treated with oral medications with or without insulin: A population-based study
You-Bin Lee, Yoon-Jong Bae, Hoseob Kim, Jiyun Park, So Yoon Kwon, So Hee Park, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin
Diabetes Research and Clinical Practice.2022; 192: 110083. CrossRef
Blood Pressure Target in Type 2 Diabetes Mellitus
Hyun-Jin Kim, Kwang-il Kim
Diabetes & Metabolism Journal.2022; 46(5): 667. CrossRef
Application Value of Systemic Inflammatory Indexes in the Clinical Evaluation of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
Ruxin Wang, Juan Wu, Haowen Ye, Xiaofang Zhang, Lihong Wang
Medicina.2022; 58(10): 1473. CrossRef
HFpEF and Atrial Fibrillation: The Enigmatic Interplay of Dysmetabolism, Biomarkers, and Vascular Endothelial Dysfunction
Jure Bosanac, Lara Straus, Marko Novaković, Daniel Košuta, Mojca Božič Mijovski, Jerneja Tasič, Borut Jug, Azizah Ugusman
Disease Markers.2022; 2022: 1. CrossRef
The importance of caveolin as a target in the prevention and treatment of diabetic cardiomyopathy
Weiyi Xia, Xia Li, Qingping Wu, Aimin Xu, Liangqing Zhang, Zhengyuan Xia
Frontiers in Immunology.2022;[Epub] CrossRef
Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes
Fu-Rong Li, Daniel Nyarko Hukportie, Jing Yang, Huan-Huan Yang, Guo-Chong Chen, Xian-Bo Wu
Diabetes Care.2022; 45(12): 2999. CrossRef
C-reactive protein and statins in heart failure with reduced and preserved ejection fraction
Jin Joo Park, Minjae Yoon, Hyoung-Won Cho, Hyun-Jai Cho, Kye Hun Kim, Dong Heon Yang, Byung-Su Yoo, Seok-Min Kang, Sang Hong Baek, Eun-Seok Jeon, Jae-Joong Kim, Myeong-Chan Cho, Shung Chull Chae, Byung-Hee Oh, Dong-Ju Choi
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond
Angela Sciacqua, Elena Succurro, Giuseppe Armentaro, Sofia Miceli, Daniele Pastori, Giuseppe Rengo, Giorgio Sesti
Heart Failure Reviews.2021; 28(3): 667. CrossRef

Original Article

COVID-19
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19: Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim; Diabetes Metab J. 2021;45(2):251-259. Published online March 5, 2021; DOI: https://doi.org/10.4093/dmj.2020.0206

7,847 View
406 Download
33 Web of Science
34 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
Dipeptidyl peptidase-4 inhibitor (DPP-4i) and renin-angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM).
Methods
As of May 2020, analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Insurance Review and Assessment Service (HIRA) database in Korea. Using this dataset, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade. Additionally, we validated the results using the National Health Insurance Service (NHIS) of Korea dataset.
Results
Totally, data of 67,850 subjects were accessible in the HIRA dataset. Of these, 5,080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 (95% confidence interval [CI], 0.135 to 0.971), and that for RAS blockade users was 0.599 (95% CI, 0.251 to 1.431). These findings were consistent with the analysis based on the NHIS data using 704 final subjects. The adjusted odds ratio for severe treatment among DPP-4i users was 0.303 (95% CI, 0.135 to 0.682), and that for RAS blockade users was 0.811 (95% CI, 0.391 to 1.682).
Conclusion
This study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19.

Citations

Citations to this article as recorded by

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
Salvatore Greco, Vincenzo M. Monda, Giorgia Valpiani, Nicola Napoli, Carlo Crespini, Fabio Pieraccini, Anna Marra, Angelina Passaro
Biomedicines.2023; 11(8): 2292. CrossRef
Efficacy and Safety of Sitagliptin in the Treatment of COVID-19
Ehab Mudher Mikhael, Siew Chin Ong, Siti Maisharah Sheikh Ghadzi
Journal of Pharmacy Practice.2023; 36(4): 980. CrossRef
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu
Future Virology.2023; 18(5): 321. CrossRef
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
Diabetologia.2023; 66(8): 1395. CrossRef
ACE2, ACE, DPPIV, PREP and CAT L enzymatic activities in COVID-19: imbalance of ACE2/ACE ratio and potential RAAS dysregulation in severe cases
Raquel Leão Neves, Jéssica Branquinho, Júlia Galanakis Arata, Clarissa Azevedo Bittencourt, Caio Perez Gomes, Michelle Riguetti, Gustavo Ferreira da Mata, Danilo Euclides Fernandes, Marcelo Yudi Icimoto, Gianna Mastroianni Kirsztajn, João Bosco Pesquero
Inflammation Research.2023; 72(8): 1719. CrossRef
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
Archives of Medical Research.2022; 53(2): 186. CrossRef
Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
Diabetes & Metabolism.2022; 48(1): 101307. CrossRef
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary Care Diabetes.2022; 16(1): 162. CrossRef
Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
Romil Singh, Sawai Singh Rathore, Hira Khan, Abhishek Bhurwal, Mack Sheraton, Prithwish Ghosh, Sohini Anand, Janaki Makadia, Fnu Ayesha, Kiran S. Mahapure, Ishita Mehra, Aysun Tekin, Rahul Kashyap, Vikas Bansal
Frontiers in Medicine.2022;[Epub] CrossRef
Short- and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes
K Zhan, X Zhang, B Wang, Z Jiang, X Fang, S Yang, H Jia, L Li, G Cao, K Zhang, X Ma
QJM: An International Journal of Medicine.2022; 115(3): 131. CrossRef
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients
Ákos Nádasdi, György Sinkovits, Ilona Bobek, Botond Lakatos, Zsolt Förhécz, Zita Z Prohászka, Marienn Réti, Miklós Arató, Gellért Cseh, Tamás Masszi, Béla Merkely, Péter Ferdinandy, István Vályi-Nagy, Zoltán Prohászka, Gábor Firneisz
Biomarkers in Medicine.2022; 16(5): 317. CrossRef
Management von Diabetespatienten in der COVID-19-Pandemie
Charlotte Steenblock, Carlotta Hoffmann, Tilman D. Rachner, Florian Guggenbichler, Ermal Tahirukaj, Sacipi Bejtullah, Vsevolod A. Zinserling, Zsuzanna Varga, Stefan R. Bornstein, Nikolaos Perakakis
Diabetes aktuell.2022; 20(01): 43. CrossRef
Letter: Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients (J Obes Metab Syndr 2021;30:149-54)
Tae Jung Oh
Journal of Obesity & Metabolic Syndrome.2022; 31(1): 86. CrossRef
Glucose-Lowering Agents and COVID-19
Ah Reum Khang
The Journal of Korean Diabetes.2022; 23(1): 1. CrossRef
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
Frontiers in Endocrinology.2022;[Epub] CrossRef
Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients
Verena Schöning, Felix Hammann
Pharmaceutics.2022; 14(9): 1828. CrossRef
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Inés Díaz-Laviada
Biomedicines.2022; 10(8): 2026. CrossRef
Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19
Aliah Alshanwani, Tarek Kashour, Amira Badr
Endocrine, Metabolic & Immune Disorders - Drug Targets.2022; 22(6): 571. CrossRef
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
World Journal of Virology.2022; 11(6): 399. CrossRef
Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
Xiao-Ce Dai, Zhuo-Yu An, Zi-Yang Wang, Zi-Zhen Wang, Yi-Ren Wang
Frontiers in Cardiovascular Medicine.2021;[Epub] CrossRef
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis
Sabrina Schlesinger, Manuela Neuenschwander, Alexander Lang, Kalliopi Pafili, Oliver Kuss, Christian Herder, Michael Roden
Diabetologia.2021; 64(7): 1480. CrossRef
Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications
Mariana Alves, Marília Andreia Fernandes, Gülistan Bahat, Athanase Benetos, Hugo Clemente, Tomasz Grodzicki, Manuel Martínez-Sellés, Francesco Mattace-Raso, Chakravarthi Rajkumar, Andrea Ungar, Nikos Werner, Timo E. Strandberg, Grodzicki, Strandberg
European Geriatric Medicine.2021; 12(4): 725. CrossRef
Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19
Jose Manuel Ramos-Rincón, Luis M Pérez-Belmonte, Francisco Javier Carrasco-Sánchez, Sergio Jansen-Chaparro, Mercedes De-Sousa-Baena, José Bueno-Fonseca, Maria Pérez-Aguilar, Coral Arévalo-Cañas, Marta Bacete Cebrian, Manuel Méndez-Bailón, Isabel Fiteni Me
The Journals of Gerontology: Series A.2021; 76(8): e102. CrossRef
Managing diabetes in diabetic patients with COVID: where do we start from?
Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
Acta Diabetologica.2021; 58(11): 1441. CrossRef
The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data
João Malato, Franziska Sotzny, Sandra Bauer, Helma Freitag, André Fonseca, Anna D. Grabowska, Luís Graça, Clara Cordeiro, Luís Nacul, Eliana M. Lacerda, Jesus Castro-Marrero, Carmen Scheibenbogen, Francisco Westermeier, Nuno Sepúlveda
Heliyon.2021; 7(8): e07665. CrossRef
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Sang Youl Rhee
Diabetes & Metabolism Journal.2021; 45(4): 619. CrossRef
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Guntram Schernthaner
Diabetes & Metabolism Journal.2021; 45(4): 615. CrossRef
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, Andreas Linkermann, Paul Zimmet, Konstantin Kulebyakin, Vsevolod A Tkachuk, Alexander G Markov, Hendrik Lehnert, Martin Hrabě de Angelis, Hannes Rietzsch, Roman N Rodionov, Kamlesh Khunti, David Hop
The Lancet Diabetes & Endocrinology.2021; 9(11): 786. CrossRef
Diabetes, Obesity, and COVID-19
Sang Youl Rhee
The Journal of Korean Diabetes.2021; 22(3): 174. CrossRef
Sunlight Exposure and Phototherapy: Perspectives for Healthy Aging in an Era of COVID-19
Toshiaki Nakano, Kuei-Chen Chiang, Chien-Chih Chen, Po-Jung Chen, Chia-Yun Lai, Li-Wen Hsu, Naoya Ohmori, Takeshi Goto, Chao-Long Chen, Shigeru Goto
International Journal of Environmental Research and Public Health.2021; 18(20): 10950. CrossRef
Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
Kardiologiia.2021; 61(9): 20. CrossRef
Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545. CrossRef
COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
Frontiers in Endocrinology.2021;[Epub] CrossRef
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
Tianli Zhang, Xiang Tong, Shijie Zhang, Dongguang Wang, Lian Wang, Qian Wang, Hong Fan
Frontiers in Pharmacology.2021;[Epub] CrossRef

Review

Drug/Regimen
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation: Päivi Maria Paldánius; Diabetes Metab J. 2020;44(6):785-801. Published online September 15, 2020; DOI: https://doi.org/10.4093/dmj.2020.0179

7,109 View
287 Download

Abstract PDF PubReader ePub: Type 2 diabetes mellitus (T2DM) is a complex and progressive chronic disease characterised by elevating hyperglycaemia and associated need to gradually intensify therapy in order to achieve and maintain glycaemic control. Treating hyperglycaemia with sequential therapy is proposed to allow holistic assessment of the efficacy and risk-to-benefit ratio of each added component. However, there is an array of evidence supporting the scientific rationale for using synergistic, earlier, modern drug combinations to achieve glycaemic goals, delay the deterioration of glycaemic control, and, therefore, potentially preserve or slow down the declining β-cell function. Additionally, implementation of early combination(s) may lead to opportunities to combat clinical inertia and other hurdles to optimised disease management outcomes. This review aims to discuss the latest empirical evidence for long-term clinical benefits of this novel strategy of early combination in people with newly diagnosed T2DM versus the current widely-implemented treatment paradigm, which focuses on control of hyperglycaemia using lifestyle interventions followed by sequentially intensified (mostly metformin-based) monotherapy. The recent reported Vildagliptin Efficacy in combination with metfoRmin For earlY treatment of T2DM (VERIFY) study results have provided significant new evidence confirming long-term glycaemic durability and tolerability of a specific early combination in the management of newly diagnosed, treatment-naïve patients worldwide. These results have also contributed to changes in clinical treatment guidelines and standards of care while clinical implementation and individualised treatment decisions based on VERIFY results might face barriers beyond the existing scientific evidence.

Original Article

Drug/Regimen
Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study: Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim; Diabetes Metab J. 2020;44(1):67-77. Published online July 11, 2019; DOI: https://doi.org/10.4093/dmj.2018.0274

7,514 View
156 Download
5 Web of Science
7 Crossref

Abstract PDF PubReader

Background

There is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. This study assessed the efficacy and safety of pioglitazone or glimepiride when added to metformin plus alogliptin treatment for T2DM.

Methods

This multicenter, randomized, active-controlled trial (ClinicalTrials.gov: NCT02426294) recruited 135 Korean patients with T2DM that was inadequately controlled using metformin plus alogliptin. The patients were then randomized to also receive pioglitazone (15 mg/day) or glimepiride (2 mg/day) for a 26-week period, with dose titration was permitted based on the investigator's judgement.

Results

Glycosylated hemoglobin levels exhibited similar significant decreases in both groups during the treatment period (pioglitazone: −0.81%, P<0.001; glimepiride: −1.05%, P<0.001). However, the pioglitazone-treated group exhibited significantly higher high density lipoprotein cholesterol levels (P<0.001) and significantly lower homeostatic model assessment of insulin resistance values (P<0.001). Relative to pioglitazone, adding glimepiride to metformin plus alogliptin markedly increased the risk of hypoglycemia (pioglitazone: 1/69 cases [1.45%], glimepiride: 14/66 cases [21.21%]; P<0.001).

Conclusion

Among patients with T2DM inadequately controlled using metformin plus alogliptin, the addition of pioglitazone provided comparable glycemic control and various benefits (improvements in lipid profiles, insulin resistance, and hypoglycemia risk) relative to the addition of glimepiride.

Citations

Citations to this article as recorded by

Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus
Yu.V. Strunina, N.A. Petunina
Medical Technologies. Assessment and Choice.2023; (3): 70. CrossRef
Pioglitazone-Enhanced Brown Fat Whitening Contributes to Weight Gain in Diet-Induced Obese Mice
Piaojian Yu, Wei Wang, Wanrong Guo, Lidan Cheng, Zhiping Wan, Yanglei Cheng, Yunfeng Shen, Fen Xu
Experimental and Clinical Endocrinology & Diabetes.2023; 131(11): 595. CrossRef
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
Joaquim Barreto, Beatriz Luchiari, Vaneza L. W. Wolf, Isabella Bonilha, Ticiane G. Bovi, Barbara S. Assato, Ikaro Breder, Sheila T. Kimura-Medorima, Daniel B. Munhoz, Thiago Quinaglia, Otavio R. Coelho-Filho, Luiz Sergio F. Carvalho, Wilson Nadruz, Andrei
Diagnostics.2022; 12(4): 814. CrossRef
Effects of Glimepiride Combined with Recombinant Human Insulin Injection on Serum IGF-1, VEGF and TRACP-5b Oxidative Stress Levels in Patients with Type 2 Diabetes Mellitus
Xue Chen, Sheng Kang, Zeqing Bao, Ciara Hughes
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2021; 23(2): 609. CrossRef
Development and validation of a sensitive LC-MS/MS method for pioglitazone: application towards pharmacokinetic and tissue distribution study in rats
Kusuma Kumari G., Praveen Thaggikuppe Krishnamurthy, Ravi Kiran Ammu V. V. V., Kurawattimath Vishwanath, S. T. Narenderan, B. Babu, Nagappan Krishnaveni
RSC Advances.2021; 11(19): 11437. CrossRef
Compliance with Cardiovascular Prevention Guidelines in Individuals with Type 2 Diabetes in a Middle-Income Region: Cross-Sectional Analysis
Joaquim Barreto, Beatriz Luchiari, Vaneza Lira W. Wolf, Isabella Bonilha, Ticiane G. Bovi, Barbara S. Assato, Ikaro Breder, Sheila T. Kimura-Medorima, Daniel B. Munhoz, Thiago Quinaglia, Otavio R. Coelho-Filho, Luiz Sérgio Fernandes de Carvalho, Wilson Na
SSRN Electronic Journal .2021;[Epub] CrossRef

Review

Genetics
Maturity-Onset Diabetes of the Young: What Do Clinicians Need to Know?: Sung-Hoon Kim; Diabetes Metab J. 2015;39(6):468-477. Published online December 11, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.6.468

6,491 View
125 Download
67 Web of Science
78 Crossref

Abstract PDF PubReader

Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes that is characterized by an early onset, autosomal dominant mode of inheritance and a primary defect in pancreatic β-cell function. MODY represents less than 2% of all diabetes cases and is commonly misdiagnosed as type 1 or type 2 diabetes mellitus. At least 13 MODY subtypes with distinct genetic etiologies have been identified to date. A correct genetic diagnosis is important as it often leads to personalized treatment for those with diabetes and enables predictive genetic testing for their asymptomatic relatives. Next-generation sequencing may provide an efficient method for screening mutations in this form of diabetes as well as identifying new MODY genes. In this review, I discuss a current update on MODY in the literatures and cover the studies that have been performed in Korea.

Citations

Citations to this article as recorded by

Alteraciones en el NeuroD1. Causa infrecuente de diabetes infantil y juvenil
Ana Isabel García Muñoz, María José Ballester Herrera, Elena Martín Campagne, Enrique Palomo Atance
Endocrinología, Diabetes y Nutrición.2023; 70(6): 438. CrossRef
An insulin hypersecretion phenotype precedes pancreatic β cell failure in MODY3 patient-specific cells
Florian M. Hermann, Maya Friis Kjærgaard, Chenglei Tian, Ulf Tiemann, Abigail Jackson, Lars Rønn Olsen, Maria Kraft, Per-Ola Carlsson, Iina M. Elfving, Jarno L.T. Kettunen, Tiinamaija Tuomi, Ivana Novak, Henrik Semb
Cell Stem Cell.2023; 30(1): 38. CrossRef
Prevalence of maturity-onset diabetes of the young in phenotypic type 2 diabetes in young adults: a nationwide, multi-center, cross-sectional survey in China
Yan Chen, Jing Zhao, Xia Li, Zhiguo Xie, Gan Huang, Xiang Yan, Houde Zhou, Li Zheng, Tao Xu, Kaixin Zhou, Zhiguang Zhou
Chinese Medical Journal.2023; 136(1): 56. CrossRef
In Silico Molecular Docking Studies of Phytocompounds From Coleus Amboinicus Against Glucokinase
Soosai Marian Anthony Ammal, Sai Sudha, Durairaj Rajkumar, Adhithya Baskaran, Gunasekaran Krishnamoorthy , Madurai Kannan Anbumozhi
Cureus.2023;[Epub] CrossRef
The Pathogenesis of Diabetes
Huiqin Guo, Haili Wu, Zhuoyu Li
International Journal of Molecular Sciences.2023; 24(8): 6978. CrossRef
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav
International Journal of Diabetes in Developing Countries.2023; 43(6): 856. CrossRef
A young‐onset type 2 diabetic Chinese girl with familial renal glycosuria caused by a novel mutation in SLC5A2: A case report
Yuqing Qu, Limei Hao, Xianling Wang
Journal of Diabetes.2023; 15(7): 622. CrossRef
Genetic and clinical characteristics of Turkish children with Maturity Onset Diabetes of the Young Type 2 (MODY2): A single center experience
Özlem NALBANTOĞLU, Semra GÜRSOY, Tarık KIRKGÖZ, Filiz HAZAN, Behzat ÖZKAN
Interdisciplinary Medical Journal.2023; 14(48): 51. CrossRef
Alterations in NeuroD1. Infrequent cause of infantile and juvenile diabetes
Ana Isabel García Muñoz, María José Ballester Herrera, Elena Martín Campagne, Enrique Palomo Atance
Endocrinología, Diabetes y Nutrición (English ed.).2023; 70(6): 438. CrossRef
Quantitative profiling and diagnostic potential of one-carbon and central metabolism pools in MODY2 and T1DM
Jieying Liu, Ziyan Xie, Junling Fu, Miao Yu, Tong Wang, Cuijuan Qi, Peng Liu, Xiangyi Hui, Dongmei Wang, Lu Ding, Qian Zhang, Ting Xie, Xinhua Xiao
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Genetic perspectives on childhood monogenic diabetes: Diagnosis, management, and future directions
Hong-Yan Sun, Xiao-Yan Lin
World Journal of Diabetes.2023; 14(12): 1738. CrossRef
Molecular and clinical assessment of maturity-onset diabetes of the young revealed low mutational rate in Moroccan families
Said Trhanint, Laila Bouguenouch, Sana Abourazzak, Hanan El Ouahabi, Hanane Latrech, Salma Benyakhlef, Bahia Bennani, Ihssane El Bouchikhi, Fatima Zahra Moufid, Karim Ouldim, Lahsen El Ghadraoui, Nadia Maazouzi
International Journal of Pediatrics and Adolescent Medicine.2022; 9(2): 98. CrossRef
Multi-ethnic GWAS and fine-mapping of glycaemic traits identify novel loci in the PAGE Study
Carolina G. Downie, Sofia F. Dimos, Stephanie A. Bien, Yao Hu, Burcu F. Darst, Linda M. Polfus, Yujie Wang, Genevieve L. Wojcik, Ran Tao, Laura M. Raffield, Nicole D. Armstrong, Hannah G. Polikowsky, Jennifer E. Below, Adolfo Correa, Marguerite R. Irvin,
Diabetologia.2022; 65(3): 477. CrossRef
When do we need to suspect maturity onset diabetes of the young in patients with type 2 diabetes mellitus?
Özlem Üstay, Tugçe Apaydın, Onur Elbasan, Hamza Polat, Gizem Günhan, Ceyda Dinçer, Lamia Şeker, Esra Arslan Ateş, Ayşegül Yabacı, Ahmet lter Güney, Dilek Gogas Yavuz
Archives of Endocrinology and Metabolism.2022;[Epub] CrossRef
Precision Diagnosis of Maturity-Onset Diabetes of the Young with Next-Generation Sequencing: Findings from the MODY-IST Study in Adult Patients
Hulya Yilmaz Aydogan, Nurdan Gul, Deniz Kanca Demirci, Ummu Mutlu, Gizem Gulfidan, Kazim Yalcin Arga, Aclan Ozder, Ahmet Adil Camli, Yildiz Tutuncu, Oguz Ozturk, Canan Cacina, Feyza Darendeliler, Sukran Poyrazoglu, Ilhan Satman
OMICS: A Journal of Integrative Biology.2022; 26(4): 218. CrossRef
Clinical Characteristics of Patients With HNF1-alpha MODY: A Literature Review and Retrospective Chart Review
Qinying Zhao, Li Ding, Ying Yang, Jinhong Sun, Min Wang, Xin Li, Ming Liu
Frontiers in Endocrinology.2022;[Epub] CrossRef
ABCC8 ‐related maturity‐onset diabetes of the young: Clinical features and genetic analysis of one case
Yun Zhou, Yan Sun, Chao Xu, Fan Liu, Yuye Gao, Caihong Liu, Yu Qiao, Jianmei Yang, Guimei Li
Pediatric Diabetes.2022; 23(5): 588. CrossRef
Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12)
Juyi Li, Xiufang Wang, Huihui Mao, Li Wen, Aiping Deng, Yarong Li, Hongmei Zhang, Chao Liu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Early-onset diabetes involving three consecutive generations had different clinical features from age-matched type 2 diabetes without a family history in China
Da-Wei Wang, Jing Yuan, Fang-yuan Yang, Hai-Yan Qiu, Jing Lu, Jin-Kui Yang
Endocrine.2022; 78(1): 47. CrossRef
UDP-glucose, cereblon-dependent proinsulin degrader
Jaeyong Cho, Atsushi Miyagawa, Kazuki Yamaguchi, Wakana Abe, Yoji Tsugawa, Hatsuo Yamamura, Takeshi Imai
Scientific Reports.2022;[Epub] CrossRef
Maturity-Onset Diabetes of the Young: Mutations, Physiological Consequences, and Treatment Options
Hazar Younis, Se Eun Ha, Brian G. Jorgensen, Arushi Verma, Seungil Ro
Journal of Personalized Medicine.2022; 12(11): 1762. CrossRef
Diagnosis and Treatment of Monogenic Forms of Diabetes Mellitus: Focus on Mody-Diabetes
K. A. Aitbaev, I. T. Murkamilov, Zh. A. Murkamilova, V. V. Fomin, I. O Kudaibergenova, F. A. Yusupov
The Russian Archives of Internal Medicine.2022; 12(6): 430. CrossRef
The Genetic Spectrum of Maturity-Onset Diabetes of the Young (MODY) in Qatar, a Population-Based Study
Asma A. Elashi, Salman M. Toor, Ilhame Diboun, Yasser Al-Sarraj, Shahrad Taheri, Karsten Suhre, Abdul Badi Abou-Samra, Omar M. E. Albagha
International Journal of Molecular Sciences.2022; 24(1): 130. CrossRef
MODY patients exhibit shorter telomere length than non‐diabetic subjects
Andrea L. Millan, Sofía I. Trobo, Alejandro de Dios, Martina Cerrato García, María S. Pérez, Gloria E. Cerrone, Gustavo D. Frechtel, Ariel P. López
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Autosomal dominant diabetes associated with a novel ZYG11A mutation resulting in cell cycle arrest in beta-cells
Chutima Charoensuk, Prapaporn Jungtrakoon Thamtarana, Chutima Chanprasert, Watip Tangjittipokin, Jun Shirakawa, Yu Togashi, Kazuki Orime, Pucharee Songprakhon, Chartchai Chaichana, Zuroida Abubakar, Paweena Ouying, Jatuporn Sujjitjoon, Alessandro Doria, N
Molecular and Cellular Endocrinology.2021; 522: 111126. CrossRef
Late Diagnosis of Maturity-Onset Diabetes of the Young 12 With Catastrophic Consequences
Nuno R Carreira, Catarina Gonçalves, Alexandra Wahnon, Sara Dâmaso, Joao Martins
Cureus.2021;[Epub] CrossRef
Vanillic acid mitigates the impairments in glucose metabolism in HepG2 cells through BAD–GK interaction during hyperinsulinemia
Mohan Sreelekshmi, Kozhiparambil Gopalan Raghu
Journal of Biochemical and Molecular Toxicology.2021; 35(6): 1. CrossRef
Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis
Luisa Sturiale, Marie-Cécile Nassogne, Angelo Palmigiano, Angela Messina, Immacolata Speciale, Rosangela Artuso, Gaetano Bertino, Nicole Revencu, Xavier Stephénne, Cristina De Castro, Gert Matthijs, Rita Barone, Jaak Jaeken, Domenico Garozzo
iScience.2021; 24(4): 102323. CrossRef
A Clinical Prediction Model to Distinguish Maturity-Onset Diabetes of the Young From Type 1 and Type 2 Diabetes in the Chinese Population
Junling Fu, Fan Ping, Tong Wang, Yiwen Liu, Xiaojing Wang, Jie Yu, Mingqun Deng, Jieying Liu, Qian Zhang, Miao Yu, Ming Li, Yuxiu Li, Xinhua Xiao
Endocrine Practice.2021; 27(8): 776. CrossRef
Combination of disease duration‐to‐age at diagnosis and hemoglobin A1c‐to‐serum C‐peptide reactivity ratios predicts patient response to glucose‐lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59)
Azuma Kanatsuka, Yasunori Sato, Yoichiro Higashi, Yoshimasa Goto, Koichi Kawai, Hiroshi Maegawa
Journal of Diabetes Investigation.2021; 12(11): 1967. CrossRef
Identification of candidate gene variants of monogenic diabetes using targeted panel sequencing in early onset diabetes patients
Dong-Hwa Lee, Soo-Heon Kwak, Hee Sue Park, Eu Jeong Ku, Hyun Jeong Jeon, Tae Keun Oh
BMJ Open Diabetes Research & Care.2021; 9(1): e002217. CrossRef
Maturity Onset Diabetes of the Young—New Approaches for Disease Modelling
Dawid Skoczek, Józef Dulak, Neli Kachamakova-Trojanowska
International Journal of Molecular Sciences.2021; 22(14): 7553. CrossRef
Clinical and genetic features of maturity-onset diabetes of the young in pediatric patients: a 12-year monocentric experience
Stefano Passanisi, Giuseppina Salzano, Bruno Bombaci, Fortunato Lombardo
Diabetology & Metabolic Syndrome.2021;[Epub] CrossRef
Maturity onset diabetes of the young
Muhammad Yassir Yaqub Qureshi, Rabia Nawaz
InnovAiT: Education and inspiration for general practice.2021; 14(11): 669. CrossRef
Diagnosis and Treatment of MODY: An Updated Mini Review
Abegail Tshivhase, Tandi Matsha, Shanel Raghubeer
Applied Sciences.2021; 11(20): 9436. CrossRef
NEUROD1 mutation in an Italian patient with maturity onset diabetes of the young 6: a case report
Lucia Brodosi, Bianca Baracco, Vilma Mantovani, Loris Pironi
BMC Endocrine Disorders.2021;[Epub] CrossRef
Maturity-Onset Diabetes of Young Type 5: Diabetes with Extrapancreatic Features
Adnan Haider, Oksana Symczyk, Ayesha Hassan, Muhammad Atif Khan, Inderpreet Madahar, Dylan Holland, Wayne V. Moore
Case Reports in Endocrinology.2021; 2021: 1. CrossRef
Gençlerin Erişkin Başlangıçlı Diyabeti (MODY) Sorumlu HNF4A, GCK ve HNF1 Gen Varyasyonlarının Dünya Genelinde Coğrafik Dağılımı
Deniz KANCA DEMİRCİ, Nurdan GÜL, İlhan SATMAN, Oguz OZTURK, Hülya YILMAZ AYDOĞAN
Haliç Üniversitesi Fen Bilimleri Dergisi.2021; 4(1): 41. CrossRef
Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL
Wolfgang Landgraf, David R. Owens, Brian M. Frier, Mei Zhang, Geremia B. Bolli
Diabetes, Obesity and Metabolism.2020; 22(3): 315. CrossRef
Molecular and clinical characteristics of monogenic diabetes mellitus in southern Chinese children with onset before 3 years of age
Yunting Lin, Huiying Sheng, Tzer Hwu Ting, Aijing Xu, Xi Yin, Jing Cheng, Huifen Mei, Yongxian Shao, Chunhua Zeng, Wen Zhang, Min Rao, Li Liu, Xiuzhen Li
BMJ Open Diabetes Research & Care.2020; 8(1): e001345. CrossRef
Maturity-onset diabetes of the young type 5 a MULTISYSTEMIC disease: a CASE report of a novel mutation in the HNF1B gene and literature review
Juan Camilo Mateus, Carolina Rivera, Miguel O’Meara, Alex Valenzuela, Fernando Lizcano
Clinical Diabetes and Endocrinology.2020;[Epub] CrossRef
Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management
Sofia Castro Oliveira, João Sérgio Neves, Antonio Pérez, Davide Carvalho
Endocrinología, Diabetes y Nutrición (English ed.).2020; 67(2): 137. CrossRef
Maturity-Onset Diabetes of the Young (MODY) in Portugal: Novel GCK, HNFA1 and HNFA4 Mutations
Maria I. Alvelos, Catarina I. Gonçalves, Eduarda Coutinho, Joana T. Almeida, Margarida Bastos, Maria L. Sampaio, Miguel Melo, Sofia Martins, Isabel Dinis, Alice Mirante, Leonor Gomes, Joana Saraiva, Bernardo D. Pereira, Susana Gama-de-Sousa, Carolina More
Journal of Clinical Medicine.2020; 9(1): 288. CrossRef
Maturity-onset diabetes of the young: update and perspectives on diagnosis and treatment
Kyung Mi Jang
Yeungnam University Journal of Medicine.2020; 37(1): 13. CrossRef
Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management
Sofia Castro Oliveira, João Sérgio Neves, Antonio Pérez, Davide Carvalho
Endocrinología, Diabetes y Nutrición.2020; 67(2): 137. CrossRef
A rare combination of MODY5 and duodenal atresia in a patient: a case report
Tao Du, Nan Zeng, Xiaofang Wen, Peizhuang Zhu, Wangen Li
BMC Medical Genetics.2020;[Epub] CrossRef
Molecular genetic study in a cohort of Iranian families suspected to maturity-onset diabetes of the young, reveals a recurrent mutation and a high-risk variant in the CEL gene
Akram Sarmadi, Aliasgar Mohammadi, Fatemeh Tabatabaei, Zahra Nouri, MortezaHashemzadeh Chaleshtori, MohammadAmin Tabatabaiefar
Advanced Biomedical Research.2020; 9(1): 25. CrossRef
Update on Monogenic Diabetes in Korea
Ye Seul Yang, Soo Heon Kwak, Kyong Soo Park
Diabetes & Metabolism Journal.2020; 44(5): 627. CrossRef
Pyruvate Kinase Controls Signal Strength in the Insulin Secretory Pathway
Sophie L. Lewandowski, Rebecca L. Cardone, Hannah R. Foster, Thuong Ho, Evgeniy Potapenko, Chetan Poudel, Halena R. VanDeusen, Sophia M. Sdao, Tiago C. Alves, Xiaojian Zhao, Megan E. Capozzi, Arnaldo H. de Souza, Ishrat Jahan, Craig J. Thomas, Craig S. Nu
Cell Metabolism.2020; 32(5): 736. CrossRef
Aberrant Sialylation in a Patient with a HNF1α Variant and Liver Adenomatosis
Luisa Sturiale, Marie-Cécile Nassogne, Angelo Palmigiano, Angela Messina, Immacolata Speciale, Rosangela Artuso, Sabrina Rita Giglio, Gaetano Bertino, Nicole Revencu, Xavier Stephénne, Cristina De Castro, Gert Matthijs, Rita Barone, Jaak Jaeken, Domenico
SSRN Electronic Journal .2020;[Epub] CrossRef
Pathophysiology of diabetes: An overview
Mujeeb Z Banday, Aga S Sameer, Saniya Nissar
Avicenna Journal of Medicine.2020; 10(04): 174. CrossRef
Genetic characterization of suspected MODY patients in Tunisia by targeted next-generation sequencing
Hamza Dallali, Serena Pezzilli, Meriem Hechmi, Om Kalthoum Sallem, Sahar Elouej, Haifa Jmel, Yosra Ben Halima, Mariem Chargui, Mariem Gharbi, Luana Mercuri, Federica Alberico, Tommaso Mazza, Afaf Bahlous, Melika Ben Ahmed, Henda Jamoussi, Abdelmajid Abid,
Acta Diabetologica.2019; 56(5): 515. CrossRef
MODY-Diabetes
Sabina Baumgartner-Parzer
Journal für Klinische Endokrinologie und Stoffwechsel.2019; 12(4): 165. CrossRef
Identification of a novel mutation site in maturity‑onset diabetes of the young in a Chinese family by whole‑exome sequencing
Han Yu, Jingjin Liu, Xiaofei Li, Fang Miao, Yanlan Yang
Molecular Medicine Reports.2019;[Epub] CrossRef
How can maturity-onset diabetes of the young be identified among more common diabetes subtypes?
Jana Urbanova, Ludmila Brunerova, Jan Broz
Wiener klinische Wochenschrift.2019; 131(17-18): 435. CrossRef
Using Clinical Indices to Distinguish MODY2 (GCK Mutation) and MODY3 (HNF1A Mutation) from Type 1 Diabetes in a Young Chinese Population
Junling Fu, Tong Wang, Jieying Liu, Xiaojing Wang, Qian Zhang, Ming Li, Xinhua Xiao
Diabetes Therapy.2019; 10(4): 1381. CrossRef
First Report of Diabetes Phenotype due to a Loss-of-Function ABCC8 Mutation Previously Known to Cause Congenital Hyperinsulinism
Theocharis Koufakis, Amalia Sertedaki, Elizabeth-Barbara Tatsi, Christina-Maria Trakatelli, Spyridon N. Karras, Eleni Manthou, Christina Kanaka-Gantenbein, Kalliopi Kotsa
Case Reports in Genetics.2019; 2019: 1. CrossRef
Birthweight correlates with later metabolic abnormalities in Chinese patients with maturity-onset diabetes of the young type 2
Junling Fu, Tong Wang, Jieying Liu, Xiaojing Wang, Ming Li, Xinhua Xiao
Endocrine.2019; 65(1): 53. CrossRef
Molecular and cellular regulation of human glucokinase
Shawn M. Sternisha, Brian G. Miller
Archives of Biochemistry and Biophysics.2019; 663: 199. CrossRef
Genetic studies of multifactorial diseases in the concept of personalized medicine
N. N. Belushkina, A. S. Chemezov, M. A. Paltsev
Profilakticheskaya meditsina.2019; 22(3): 26. CrossRef
Epigenome-wide association study in peripheral white blood cells involving insulin resistance
Ana Arpón, Fermín I. Milagro, Omar Ramos-Lopez, M. Luisa Mansego, José Luis Santos, José-Ignacio Riezu-Boj, J. Alfredo Martínez
Scientific Reports.2019;[Epub] CrossRef
Maturity Onset Diabetes of the Young: A Rare Monogenic Form of Diabetes
Kallarackal M
International Journal of Clinical Endocrinology and Metabolism.2019; : 006. CrossRef
Hidden MODY—Looking for a Needle in a Haystack
Jana Urbanová, Ludmila Brunerová, Jan Brož
Frontiers in Endocrinology.2018;[Epub] CrossRef
Fifteen-minute consultation: Monogenic forms of diabetes with onset after age 6 months
Emma M Dyer, Rakesh Amin
Archives of disease in childhood - Education & practice edition.2018; 103(2): 58. CrossRef
Aspectos clínicos y diagnósticos de la diabetes infantil
M. Louvigné, A. Decrequy, A. Donzeau, N. Bouhours-Nouet, R. Coutant
EMC - Pediatría.2018; 53(1): 1. CrossRef
Genetic Testing of Maturity-Onset Diabetes of the Young Current Status and Future Perspectives
Parveena Firdous, Kamran Nissar, Sajad Ali, Bashir Ahmad Ganai, Uzma Shabir, Toyeeba Hassan, Shariq Rashid Masoodi
Frontiers in Endocrinology.2018;[Epub] CrossRef
Applications of mesoporous silica in biosensing and controlled release of insulin
Maria Sönmez, Denisa Ficai, Anton Ficai, Laurentia Alexandrescu, Mihai Georgescu, Roxana Trusca, Dana Gurau, Mihail Aurel Titu, Ecaterina Andronescu
International Journal of Pharmaceutics.2018; 549(1-2): 179. CrossRef
Novel deletion mutation in the glucokinase gene from a Korean man with GCK-MODY phenotype and situs inversus
Yun Kyung Cho, Eun-Hee Cho, Hoon Sung Choi, Sang-Wook Kim
Diabetes Research and Clinical Practice.2018; 143: 263. CrossRef
Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations
S. Ben Khelifa, R. Martinez, A. Dandana, I. Khochtali, S. Ferchichi, L. Castaño
Gene.2018; 651: 44. CrossRef
Pregnancy Complicated by Maternal MODY 3 and Paternal MODY 2 Diabetes and Subsequent Rapidly Falling Insulin Requirement
Anastasia Mikuscheva, Adel Mekhail, Benjamin J. Wheeler
Case Reports in Obstetrics and Gynecology.2018; 2018: 1. CrossRef
Mechanistic Origins of Enzyme Activation in Human Glucokinase Variants Associated with Congenital Hyperinsulinism
Shawn M. Sternisha, Peilu Liu, Alan G. Marshall, Brian G. Miller
Biochemistry.2018; 57(10): 1632. CrossRef
Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY)
Xiuzhen Li, Tzer Hwu Ting, Huiying Sheng, Cui Li Liang, Yongxian Shao, Minyan Jiang, Aijing Xu, Yunting Lin, Li Liu
BMC Pediatrics.2018;[Epub] CrossRef
Pathway-induced allelic spectra of diseases in the presence of strong genetic effects
George Kanoungi, Michael Nothnagel
Human Genetics.2018; 137(3): 215. CrossRef
Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing
Eun-Hee Cho, Jae Woong Min, Sun Shim Choi, Hoon Sung Choi, Sang-Wook Kim
Endocrinology and Metabolism.2017; 32(2): 296. CrossRef
The HNF1A mutant Ala180Val: Clinical challenges in determining causality of a rare HNF1A variant in familial diabetes
J.V. Sagen, L. Bjørkhaug, B.I. Haukanes, L. Grevle, J. Molnes, B.G. Nedrebø, O. Søvik, P.R. Njølstad, S. Johansson, A. Molven
Diabetes Research and Clinical Practice.2017; 133: 142. CrossRef
Variants in MODY genes associated with maternal lipids profiles in second trimester of pregnancy
Xiaojing Wang, Wei Li, Liangkun Ma, Fan Ping, Juntao Liu, Xueyan Wu, Jiangfeng Mao, Xi Wang, Min Nie
The Journal of Gene Medicine.2017; 19(6-7): e2962. CrossRef
Genotype-Phenotype Correlation in a MODY 2 Family: An Under-Diagnosed Disease
Maria Chiara Fabiano, Antonella Verrienti, Antonella Carbone, Marialuisa Sponziello, Pasquale Bellitti, Rocco Bruno
Journal of Diabetes Mellitus.2016; 06(04): 263. CrossRef
Revisiting the Polygenic Additive Liability Model through the Example of Diabetes Mellitus
Emmanuelle Génin, Françoise Clerget-Darpoux
Human Heredity.2015; 80(4): 171. CrossRef

Original Articles

Safety and Efficacy of Modern Insulin Analogues: Hye Jin Yoo, Keun Yong Park, Kang Seo Park, Kyu Jeung Ahn, Kyung Wan Min, Jeong Hyun Park, Sang Ah Chang, Bong Soo Cha, Dong-Jun Kim, Yong Seong Kim, Tae Keun Oh, Suk Chon, Il Seong Nam-Goong, Mi Jin Kim, Hye-Soon Kim, Young Sik Choi, You Hern Ahn, Sora Lee, Sei Hyun Baik; Diabetes Metab J. 2013;37(3):181-189. Published online June 14, 2013; DOI: https://doi.org/10.4093/dmj.2013.37.3.181

4,116 View
32 Download
9 Crossref

Abstract PDF PubReader

Background

A1chieve® was a noninterventional study evaluating the clinical safety and efficacy of biphasic insulin aspart 30, insulin detemir, and insulin aspart.

Methods

Korean type 2 diabetes patients who have not been treated with the study insulin or have started it within 4 weeks before enrollment were eligible for the study. The patient selection and the choice of regimen were at the discretion of the physician. The safety and efficacy information was collected from the subjects at baseline, week 12, and week 24. The number of serious adverse drug reactions (SADRs) was the primary endpoint. The changes of clinical diabetic markers at week 12 and/or at week 24 compared to baseline were the secondary endpoints.

Results

Out of 4,058 exposed patients, 3,003 completed the study. During the study period, three SADRs were reported in three patients (0.1%). No major hypoglycemic episodes were observed and the rate of minor hypoglycemic episodes marginally decreased during 24 weeks (from 2.77 to 2.42 events per patient-year). The overall quality of life score improved (from 66.7±15.9 to 72.5±13.5) while the mean body weight was slightly increased (0.6±3.0 kg). The 24-week reductions in glycated hemoglobin, fasting plasma glucose and postprandial plasma glucose were 1.6%±2.2%, 2.5±4.7 mmol/L, and 4.0±6.4 mmol/L, respectively.

Conclusion

The studied regimens showed improvements in glycemic control with low incidence of SADRs, including no incidence of major hypoglycemic episodes in Korean patients with type 2 diabetes.

Citations

Citations to this article as recorded by

Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017
Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
The Korean Journal of Internal Medicine.2017; 32(6): 967. CrossRef
Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
Diabetes & Metabolism Journal.2017; 41(5): 367. CrossRef
An information and communication technology-based centralized clinical trial to determine the efficacy and safety of insulin dose adjustment education based on a smartphone personal health record application: a randomized controlled trial
Gyuri Kim, Ji Cheol Bae, Byoung Kee Yi, Kyu Yeon Hur, Dong Kyung Chang, Moon-Kyu Lee, Jae Hyeon Kim, Sang-Man Jin
BMC Medical Informatics and Decision Making.2017;[Epub] CrossRef
Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
Gyuri Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Byung-Wan Lee
Yonsei Medical Journal.2016; 57(6): 1395. CrossRef
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
Jae-Seung Yun, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2015; 30(1): 6. CrossRef
Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes
Sun Ok Song, You-Cheol Hwang, Kyu-Jeung Ahn, Bong Soo Cha, Young Duk Song, Dae Wook Lee, Byung-Wan Lee
Diabetes Therapy.2015; 6(4): 547. CrossRef
The optimal morning:evening ratio in total dose of twice‐daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24‐week multi‐centre prospective, randomized controlled, open‐labelled clinical study
C. H. Jung, J.‐Y. Park, J. H. Cho, K.‐H. Yoon, H. K. Yang, Y.‐H. Lee, B. S. Cha, B.‐W. Lee
Diabetic Medicine.2014; 31(1): 68. CrossRef
The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub‐analysis from the A 1 chieve ® study
Y.‐C. Hwang, J. G. Kang, K. J. Ahn, B. S. Cha, S.‐H. Ihm, S. Lee, M. Kim, B.‐W. Lee
International Journal of Clinical Practice.2014; 68(11): 1338. CrossRef
Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J2013;37:117-24)
Byung-Wan Lee
Diabetes & Metabolism Journal.2013; 37(3): 212. CrossRef

Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study: Juyoung Shin, Jin-Sun Chang, Hun-Sung Kim, Sun-Hee Ko, Bong-Yun Cha, Ho-Young Son, Kun-Ho Yoon, Jae-Hyoung Cho; Diabetes Metab J. 2012;36(5):364-370. Published online October 18, 2012; DOI: https://doi.org/10.4093/dmj.2012.36.5.364

3,507 View
37 Download
9 Crossref

Abstract PDF PubReader

Background

While many studies have shown the good efficacy and safety of exenatide in patients with diabetes, limited information is available about exenatide in clinical practice in Korean populations. Therefore, this retrospective cohort study was designed to analyze the effects of exenatide on blood glucose level and body weight in Korean patients with type 2 diabetes mellitus.

Methods

We reviewed the records of the patients with diabetes who visited Seoul St. Mary's Hospital and for whom exenatide was prescribed from June 2009 to October 2011. After excluding subjects based on their race/ethnicity, medical history, whether or not they changed more than 2 kinds of oral hypoglycemic agents with exenatide treatment, loss to follow-up, or whether they stopped exenatide therapy within 6 months, a total of 52 subjects were included in the final analysis.

Results

The mean glycated hemoglobin (HbA1c) level and weight remarkably decreased from 8.5±1.7% to 6.7±1.0% (P<0.001) and from 82.3±15.8 kg to 78.6±16.3 kg (P<0.001), respectively. The multiple regression analysis indicated that the reduction in HbA1c level was significantly associated with a shorter duration of diabetes, a higher baseline HbA1c level, and greater weight reduction, whereas weight loss had no significant correlation with other factors. No severe adverse events were observed.

Conclusion

These results suggest that a 6-month exenatide injection therapy significantly improved patients' HbA1c levels and body weights without causing serious adverse effects in Korean patients with type 2 diabetes.

Citations

Citations to this article as recorded by

Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes
Artemis Kyriakidou, Angeliki V. Kyriazou, Theocharis Koufakis, Yiannis Vasilopoulos, Maria Grammatiki, Xanthippi Tsekmekidou, Iakovos Avramidis, Stefanos Baltagiannis, Dimitrios G. Goulis, Pantelis Zebekakis, Kalliopi Kotsa
Journal of Personalized Medicine.2022; 12(3): 424. CrossRef
Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells
Nunzia Caporarello, Cristina Parrino, Vincenzo Trischitta, Lucia Frittitta, Claudia Miele
PLOS ONE.2017; 12(8): e0181190. CrossRef
Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
Kun-Ho Yoon, Elise Hardy, Jenny Han
Diabetes & Metabolism Journal.2017; 41(1): 69. CrossRef
Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool
Oliver Schnell, Jianping Weng, Wayne H.-H. Sheu, Hirotaka Watada, Sanjay Kalra, Sidartawan Soegondo, Noriyuki Yamamoto, Rahul Rathod, Cheryl Zhang, Wladyslaw Grzeszczak
Journal of Diabetes and its Complications.2016; 30(4): 628. CrossRef
Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
Muhammad Khan, Jing Ouyang, Karen Perkins, Sunil Nair, Franklin Joseph
Journal of Diabetes Research.2015; 2015: 1. CrossRef
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Seungjoon Oh, Suk Chon, Kyu Jeong Ahn, In-Kyung Jeong, Byung-Joon Kim, Jun Goo Kang
Diabetes & Metabolism Journal.2015; 39(3): 177. CrossRef
Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
Sun Ok Song, Kwang Joon Kim, Byung‐Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Journal of Diabetes Investigation.2014; 5(5): 554. CrossRef
From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis?
C.-Y. Chen, C.-Y. Tsai
Rheumatology.2014; 53(2): 205. CrossRef
Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
Stuart A. Ross, Jane Ballantine
Current Medical Research and Opinion.2013; 29(12): 1617. CrossRef

Review

2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea: Seung-Hyun Ko, Sung-Rea Kim, Dong-Joon Kim, Seung-Joon Oh, Hye-Jin Lee, Kang-Hee Shim, Mi-Hye Woo, Jun-Young Kim, Nan-Hee Kim, Jae-Taik Kim, Chong Hwa Kim, Hae Jin Kim, In-Kyung Jeong, Eun-Kyung Hong, Jae-Hyoung Cho, Ji-Oh Mok, Kun-Ho Yoon; Diabetes Metab J. 2011;35(5):431-436. Published online October 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.5.431

57,956 View
50 Download
99 Crossref

Abstract PDF PubReader

As in other countries, type 2 diabetes is major health concern in Korea. A dramatic increase in the prevalence of type 2 diabetes and its chronic complications has led to an increase in health costs and economic burdens. Early detection of high risk individuals, hidden diabetic patients, and improvement in the quality of care for the disease are the first steps to mitigate the increase in prevalence. The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the '3rd Clinical Practice Guidelines' at the end of 2010. In the guidelines, the committee recommended active screening of high risk individuals for early detection and added the hemoglobin A1c level to the diagnostic criteria for type 2 diabetes based on clinical studies performed in Korea. Furthermore, the committee members emphasized that integrating patient education and self-management is an essential part of care. The drug treatment algorithm based on the degree of hyperglycemia and patient characteristics were also updated.

Citations

Citations to this article as recorded by

Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection
Jong Chul Won
The Journal of Korean Diabetes.2023; 24(2): 59. CrossRef
Association of HbA1c with functional outcome by ischemic stroke subtypes and age
Jihyun Jeong, Jae Kyung Park, Young Ho Koh, Jong-Moo Park, Hee-Joon Bae, Sang-Moon Yun
Frontiers in Neurology.2023;[Epub] CrossRef
Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sung
Diabetes & Metabolism Journal.2022; 46(3): 464. CrossRef
Correlation between Serum Osmolarity and Creatinine in Health Check-Up Subjects (Examinees) with Diabetes
Mi-Kyung Park, Geum-Seon Lee, Sun-Hee Kim, Mi-Eun Yun
The Korean Journal of Community Living Science.2022; 33(2): 237. CrossRef
Dietary antioxidant consumption and the risk of type 2 diabetes in South Korean adults: a prospective cohort study based on the Health Examinees study
Li-Juan Tan, Su Bin Hwang, Shinyoung Jun, Hyojee Joung, Sangah Shin
BMJ Open.2022; 12(7): e065073. CrossRef
Investigating the Effectiveness of Very Low-Calorie Diets and Low-Fat Vegan Diets on Weight and Glycemic Markers in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Anjali Kashyap, Alexander Mackay, Ben Carter, Claire L. Fyfe, Alexandra M. Johnstone, Phyo K. Myint
Nutrients.2022; 14(22): 4870. CrossRef
Screening for Prediabetes and Diabetes in Korean Nonpregnant Adults: A Position Statement of the Korean Diabetes Association, 2022
Kyung Ae Lee, Dae Jung Kim, Kyungdo Han, Suk Chon, Min Kyong Moon
Diabetes & Metabolism Journal.2022; 46(6): 819. CrossRef
Mobile Healthcare System Provided by Primary Care Physicians Improves Quality of Diabetes Care
Tae Jung Oh, Jie-Eun Lee, Seok Kim, Sooyoung Yoo, Hak Chul Jang
CardioMetabolic Syndrome Journal.2021; 1(1): 88. CrossRef
Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000–2019
Kyung Ae Lee, Heung Yong Jin, Yu Ji Kim, Yong-Jin Im, Eun-Young Kim, Tae Sun Park
Journal of Korean Medical Science.2021;[Epub] CrossRef
A Review on Metformin: Clinical Significance and Side Effects
Mazumder Avijit, Singh Ashini
Research Journal of Pharmacy and Technology.2021; : 6179. CrossRef
Cardiovascular Disease among Patients with Diabetes: The Current Scenario in Saudi Arabia
Asirvatham Alwin Robert, Mohamed Abdulaziz Al Dawish
Current Diabetes Reviews.2021; 17(2): 180. CrossRef
Association of Cardiometabolic Multimorbidity Pattern with Dietary Factors among Adults in South Korea
Dawoon Jeong, Jieun Kim, Hansongyi Lee, Do-Yeon Kim, Hyunjung Lim
Nutrients.2020; 12(9): 2730. CrossRef
Comparison of effectiveness and drug cost between dipeptidyl peptidase‐4 inhibitor and biguanide as the first‐line anti‐hyperglycaemic medication among Japanese working generation with type 2 diabetes
Noriko Ihana‐Sugiyama, Takehiro Sugiyama, Hirokazu Tanaka, Kohjiro Ueki, Yasuki Kobayashi, Mitsuru Ohsugi
Journal of Evaluation in Clinical Practice.2020; 26(1): 299. CrossRef
Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose
Jie Huang, Wen‐yu Liu, Jing‐jing Yu, Jin‐bo Yang, Min Li, Chan Zou, Cheng‐xian Guo, Xiao‐yan Yang, Shuang Yang, Jin‐lian Xie, Zhi‐jun Huang, Hui Chen, Qi Pei, Guo‐ping Yang
British Journal of Clinical Pharmacology.2020; 86(11): 2225. CrossRef
Sex-, Age-, and Metabolic Disorder-Dependent Distributions of Selected Inflammatory Biomarkers among Community-Dwelling Adults
So Mi Jemma Cho, Hokyou Lee, Jee-Seon Shim, Hyeon Chang Kim
Diabetes & Metabolism Journal.2020; 44(5): 711. CrossRef
Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial
Linong Ji, Eun Seok Kang, XiaoLin Dong, Ling Li, GuoYue Yuan, Shuhua Shang, Elisabeth Niemoeller
Diabetes, Obesity and Metabolism.2020; 22(4): 612. CrossRef
Effect of different dietary patterns on glycemic control in individuals with type 2 diabetes mellitus: A systematic review
Gabrielli Barbosa de Carvalho, Natalia Lohayne Dias-Vasconcelos, Ramara Kadija Fonseca Santos, Paula Nascimento Brandão-Lima, Danielle Góes da Silva, Liliane Viana Pires
Critical Reviews in Food Science and Nutrition.2020; 60(12): 1999. CrossRef
Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Jeong Taek Woo
International Journal of Endocrinology.2020; 2020: 1. CrossRef
Chronic Hyperglycemia before Spinal Cord Injury Increases Inflammatory Reaction and Astrogliosis after Injury: Human and Rat Studies
Ki-Su Park, Jin Bum Kim, Martin Keung, Ye Jin Seo, Sung Young Seo, Seul Ah Mun, Young-Seok Lee, Dae-Chul Cho, Jeong-Hyun Hwang, Inbo Han, Chi Heon Kim, Kyoung-Tae Kim
Journal of Neurotrauma.2020; 37(9): 1165. CrossRef
National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus
Jisu Kim, Susin Park, Hyunsoo Kim, Nam Kyung Je
European Journal of Clinical Pharmacology.2019; 75(12): 1723. CrossRef
Three-Dimensional Paper-Based Microfluidic Analytical Devices Integrated with a Plasma Separation Membrane for the Detection of Biomarkers in Whole Blood
Chanyong Park, Hong-Rae Kim, Soo-Kyung Kim, In-Kyung Jeong, Jae-Chul Pyun, Sungsu Park
ACS Applied Materials & Interfaces.2019; 11(40): 36428. CrossRef
The Effect of Metformin on Prognosis in Patients With Locally Advanced Gastric Cancer Associated With Type 2 Diabetes Mellitus
Ho Seok Seo, Yoon Ju Jung, Ji Hyun Kim, Han Hong Lee, Cho Hyun Park
American Journal of Clinical Oncology.2019; 42(12): 909. CrossRef
Discordance in prediction for prognosis of type 2 diabetes after metabolic surgery: comparison of the ABCD, DiaRem, and individualized metabolic surgery models
Jane Ha, Yeongkeun Kwon, Nam Hoon Kim, Sungsoo Park, Emanuele Lo Menzo, Raul J. Rosenthal
Annals of Surgical Treatment and Research.2019; 97(6): 309. CrossRef
Discrepancies between Glycosylated Hemoglobin and Fasting Plasma Glucose for Diagnosing Impaired Fasting Glucose and Diabetes Mellitus in Korean Youth and Young Adults
Jieun Lee, Young Ah Lee, Jae Hyun Kim, Seong Yong Lee, Choong Ho Shin, Sei Won Yang
Diabetes & Metabolism Journal.2019; 43(2): 174. CrossRef
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Mee Kyoung Kim, Seung-Hyun Ko, Bo-Yeon Kim, Eun Seok Kang, Junghyun Noh, Soo-Kyung Kim, Seok-O Park, Kyu Yeon Hur, Suk Chon, Min Kyong Moon, Nan-Hee Kim, Sang Yong Kim, Sang Youl Rhee, Kang-Woo Lee, Jae Hyeon Kim, Eun-Jung Rhee, SungWan Chun, Sung Hoon Yu
Diabetes & Metabolism Journal.2019; 43(4): 398. CrossRef
Lack of Association between Past Helicobacter pylori Infection and Diabetes: A Two-Cohort Study
Jeung Hui Pyo, Hyuk Lee, Sung Chul Choi, Soo Jin Cho, Yoon-Ho Choi, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Heejin Yoo, Kyunga Kim, Jae J. Kim
Nutrients.2019; 11(8): 1874. CrossRef
Does Korean diet based on brown rice really have the effect on treating chronic diseases and on suspending drug use?
Su Jin Jung, Baik Hwan Cho, Soo Wan Chae
Journal of Ethnic Foods.2018;[Epub] CrossRef
The effectiveness, reproducibility, and durability of tailored mobile coaching on diabetes management in policyholders: A randomized, controlled, open-label study
Da Young Lee, Jeongwoon Park, Dooah Choi, Hong-Yup Ahn, Sung-Woo Park, Cheol-Young Park
Scientific Reports.2018;[Epub] CrossRef
Clinical Characteristics of People with Newly Diagnosed Type 2 Diabetes between 2015 and 2016: Difference by Age and Body Mass Index
Kyoung Hwa Ha, Cheol Young Park, In Kyung Jeong, Hyun Jin Kim, Sang-Yong Kim, Won Jun Kim, Ji Sung Yoon, In Joo Kim, Dae Jung Kim, Sungrae Kim
Diabetes & Metabolism Journal.2018; 42(2): 137. CrossRef
Distribution of glycated haemoglobin and its determinants in Korean youth and young adults: a nationwide population-based study
Ji-Young Seo, Seung-sik Hwang, Jae Hyun Kim, Young Ah Lee, Seong Yong Lee, Choong Ho Shin, Sei Won Yang
Scientific Reports.2018;[Epub] CrossRef
The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus
Jin-Won Noh, Jin Hee Jung, Jeong Eun Park, Jung Hwa Lee, Kang Hee Sim, Jumin Park, Min Hee Kim, Ki-Bong Yoo
Journal of Physical Therapy Science.2018; 30(2): 201. CrossRef
Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status
Jong Chul Won, Jae Hyuk Lee, Jae Hyeon Kim, Eun Seok Kang, Kyu Chang Won, Dae Jung Kim, Moon-Kyu Lee
Diabetes & Metabolism Journal.2018; 42(5): 415. CrossRef
Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data
Sejeong Park, Sang Youl Rhee, Su Jin Jeong, Kiyoung Kim, Suk Chon, Seung-Young Yu, Jeong-Taek Woo
Diabetes & Metabolism Journal.2017; 41(5): 393. CrossRef
Letter: Comparison of Age of Onset and Frequency of Diabetic Complications in the Very Elderly Patients with Type 2 Diabetes (Endocrinol Metab2016;31:416-23, Bong-Ki Lee et al.)
Mee Kyoung Kim
Endocrinology and Metabolism.2017; 32(1): 140. CrossRef
The Cutoff Value of HbA1c in Predicting Diabetes and Impaired Fasting Glucose
Seyoung Kwon, Youngak Na
The Korean Journal of Clinical Laboratory Science.2017; 49(2): 114. CrossRef
Changes in HbA 1c levels and body mass index after successful decompression surgery in patients with type 2 diabetes mellitus and lumbar spinal stenosis: results of a 2-year follow-up study
Kyoung-Tae Kim, Dae-Chul Cho, Joo-Kyung Sung, Chi Heon Kim, Hyun Kang, Du Hwan Kim
The Spine Journal.2017; 17(2): 203. CrossRef
Validation of a Newly Developed Equation for Estimating Serum Apolipoprotein B: Associations with Cardiovascular Disease Surrogate Markers in Koreans
Jong-Dai Kim, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
Yonsei Medical Journal.2017; 58(5): 975. CrossRef
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
The Korean Journal of Internal Medicine.2017; 32(6): 947. CrossRef
Diagnostic criteria for diabetes in China: are we pushing too much beyond evidence?
X Ma, Y-L Zhang, Q Ji, Y Xing, H Pan, S Chen, J-L Tang, S Zhu
European Journal of Clinical Nutrition.2017; 71(7): 812. CrossRef
Patterns, control and complications of diabetes from a hospital based registry established in a low income country
Jaweed Akhter, Asma Ahmed, Minaz Mawani, Laila Lakhani, Ayaz Kalsekar, Shehla Tabassum, Najmul Islam
BMC Endocrine Disorders.2017;[Epub] CrossRef
Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment
Yanyun Gu, Xiaokai Wang, Junhua Li, Yifei Zhang, Huanzi Zhong, Ruixin Liu, Dongya Zhang, Qiang Feng, Xiaoyan Xie, Jie Hong, Huahui Ren, Wei Liu, Jing Ma, Qing Su, Hongmei Zhang, Jialin Yang, Xiaoling Wang, Xinjie Zhao, Weiqiong Gu, Yufang Bi, Yongde Peng,
Nature Communications.2017;[Epub] CrossRef
Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
Diabetes & Metabolism Journal.2017; 41(5): 337. CrossRef
Regional variations in frequency of glycosylated hemoglobin (HbA1c) monitoring in Korea: A multilevel analysis of nationwide data
Kyoung-Hun Yoo, Dong-Wook Shin, Mi-Hee Cho, Sang-Hyuck Kim, Hyun-Jung Bahk, Shin-Hye Kim, Su-Min Jeong, Jae-Moon Yun, Jin-Ho Park, Heesun Kim, BeLong Cho
Diabetes Research and Clinical Practice.2017; 131: 61. CrossRef
Fasting plasma glucose concentrations for specified HbA1c goals in Korean populations: data from the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V-2, 2011)
Sangmo Hong, Jun Goo Kang, Chul Sik Kim, Seong Jin Lee, Chang Beom Lee, Sung-Hee Ihm
Diabetology & Metabolic Syndrome.2016;[Epub] CrossRef
Metabolic syndrome independently predicts future diabetes in women with a history of gestational diabetes mellitus
Nam H. Cho, Chang Ho Ahn, Joon Ho Moon, Soo Heon Kwak, Sung Hee Choi, Soo Lim, Kyong Soo Park, Boyd E. Metzger, Hak C. Jang
Medicine.2016; 95(35): e4582. CrossRef
Feasibility of a Patient-Centered, Smartphone-Based, Diabetes Care System: A Pilot Study
Eun Ky Kim, Soo Heon Kwak, Seungsu Baek, Seung Lyeol Lee, Hak Chul Jang, Kyong Soo Park, Young Min Cho
Diabetes & Metabolism Journal.2016; 40(3): 192. CrossRef
Effectiveness of Web-Based Interventions for Managing Diabetes in Korea
Jee Young Joo
CIN: Computers, Informatics, Nursing.2016; 34(12): 587. CrossRef
Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes
Seon-Ah Cha, Jae-Seung Yun, Tae-Seok Lim, Seawon Hwang, Eun-Jung Yim, Ki-Ho Song, Ki-Dong Yoo, Yong-Moon Park, Yu-Bae Ahn, Seung-Hyun Ko
Diabetes & Metabolism Journal.2016; 40(3): 202. CrossRef
A Potential Issue with Screening Prediabetes or Diabetes Using Serum Glucose: A Delay in Diagnosis
Jun Goo Kang, Cheol-Young Park, Sung-Hee Ihm, Sung Woo Park
Diabetes & Metabolism Journal.2016; 40(5): 414. CrossRef
Experiences of Diabetes Education among Educators of Diabetes : a content analysis approach
Soo Jin Kang, Soo Jung Chang
Journal of Korean Public Health Nursing.2016; 30(2): 221. CrossRef
Efficient Strategy to Identify Gene-Gene Interactions and Its Application to Type 2 Diabetes
Donghe Li, Sungho Won
Genomics & Informatics.2016; 14(4): 160. CrossRef
A patient-centric approach to optimise insulin therapy in Asia
Su Yen Goh, Ernesto Ang, Shailendra Bajpai, Chaicharn Deerochanawong, Eun-Gyoung Hong, Zanariah Hussein, Shashank Joshi, Nor Azmi Kamaruddin, Sjoberg Kho, Alice Pik-Shan Kong, Chang Yu Pan, Riccardo Perfetti, Apichati Vichayanrat, Aleksandra Vlajnic, Juli
Journal of Diabetes and its Complications.2016; 30(6): 973. CrossRef
Glycosylated Hemoglobin Threshold for Predicting Diabetes and Prediabetes from the Fifth Korea National Health and Nutrition Examination Survey
Sangmo Hong, Jun Goo Kang, Chul Sik Kim, Seong Jin Lee, Cheol-Young Park, Chang Beom Lee, Sung-Hee Ihm
Diabetes & Metabolism Journal.2016; 40(2): 167. CrossRef
Retrospective Observational Dose-Titration Study of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on 15 mg of Pioglitazone
So Young Ha, Hae Won Jung, Yong Jun Choi, Hyun Kyo Lee, Jong Wook Choi, Ji Hoon Choi, Jung Hyun Noh, Jae Won Hong, Dong-Jun Kim
The Journal of Korean Diabetes.2016; 17(1): 51. CrossRef
Upper-normal waist circumference is a risk marker for metabolic syndrome in normal-weight subjects
R. Okada, Y. Yasuda, K. Tsushita, K. Wakai, N. Hamajima, S. Matsuo
Nutrition, Metabolism and Cardiovascular Diseases.2016; 26(1): 67. CrossRef
Optimal Glycemic and Hemoglobin A1c Thresholds for Diagnosing Diabetes Based on Prevalence of Retinopathy in an Iranian Population
Naser Samadi Aidenloo, Alireza Mehdizadeh, Neda Valizadeh, Mohammad Abbaszadeh, Siavash Qarequran, Hamidreza Khalkhali
Iranian Red Crescent Medical Journal.2016;[Epub] CrossRef
Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013
Seung-Hyun Ko, Dae-Jung Kim, Jong-Heon Park, Cheol-Young Park, Chang Hee Jung, Hyuk-Sang Kwon, Joong-Yeol Park, Kee-Ho Song, Kyungdo Han, Ki-Up Lee, Kyung-Soo Ko
Medicine.2016; 95(27): e4018. CrossRef
Association between estimated blood glucose levels and glycated hemoglobin levels
Seon-Ah Cha, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2016; 31(3): 457. CrossRef
Uncontrolled diabetes mellitus: Prevalence and risk factors among people with type 2 diabetes mellitus in an Urban District of Karachi, Pakistan
Fahad Javaid Siddiqui, Bilal Iqbal Avan, Sadia Mahmud, Debra J. Nanan, Abdul Jabbar, Pryseley Nkouibert Assam
Diabetes Research and Clinical Practice.2015; 107(1): 148. CrossRef
Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross‐sectional, observational study in Korea
Sin Gon Kim, Jong Ryeal Hahm, Duk Kyu Kim, Sung Rae Cho, Dong Seop Choi
Journal of Diabetes Investigation.2015; 6(3): 317. CrossRef
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
Jae-Seung Yun, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2015; 30(1): 6. CrossRef
The Correlation between Hemoglobin A1c and Common Carotid Artery Intima Medial Thickness of Both Genders with Less Than 6.5% HbA1c Based on Ultrasound Measurement
Yeongju Ryu, Youngjin Park, Byeong Jin Ye
Korean Journal of Health Promotion.2015; 15(2): 47. CrossRef
Increased prevalence of albuminuria in individuals with higher range of impaired fasting glucose: the 2011 Korea National Health and Nutrition Examination Survey
Jong Chul Won, Jae Won Hong, Jung Min Kim, Tae Nyun Kim, Jung Hyun Noh, Kyung Soo Ko, Byoung Doo Rhee, Dong-Jun Kim
Journal of Diabetes and its Complications.2015; 29(1): 50. CrossRef
The Association between Chronic Kidney Disease and Diabetic Retinopathy: The Korea National Health and Nutrition Examination Survey 2008-2010
Young-Hoon Park, Jeong Ah Shin, Jae-Hyung Han, Yong-Moon Park, Hyeon Woo Yim, Harald Mischak
PLOS ONE.2015; 10(4): e0125338. CrossRef
Efficacy of a New Medical Information system, Ubiquitous Healthcare Service with Voice Inception Technique in Elderly Diabetic Patients
Kyoung Min Kim, Kyeong Seon Park, Hyun Ju Lee, Yun Hee Lee, Ji Seon Bae, Young Joon Lee, Sung Hee Choi, Hak Chul Jang, Soo Lim
Scientific Reports.2015;[Epub] CrossRef
Intensive Individualized Reinforcement Education Is Important for the Prevention of Hypoglycemia in Patients with Type 2 Diabetes
Yun-Mi Yong, Kyung-Mi Shin, Kang-Min Lee, Jae-Young Cho, Sun-Hye Ko, Min-Hyang Yoon, Tae-Won Kim, Jong-Hyun Jeong, Yong-Moon Park, Seung-Hyun Ko, Yu-Bae Ahn
Diabetes & Metabolism Journal.2015; 39(2): 154. CrossRef
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Seungjoon Oh, Suk Chon, Kyu Jeong Ahn, In-Kyung Jeong, Byung-Joon Kim, Jun Goo Kang
Diabetes & Metabolism Journal.2015; 39(3): 177. CrossRef
Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
Se Hee Min, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hye Seung Jung
Endocrinology and Metabolism.2015; 30(4): 509. CrossRef
Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes
Jae-Seung Yun, Seung-Hyun Ko, Sun-Hye Ko, Ki-Ho Song, Ki-Dong Yoo, Kun-Ho Yoon, Yong-Moon Park, Yu-Bae Ahn
Diabetes & Metabolism Journal.2015; 39(6): 498. CrossRef
Association between flavonoid intake and diabetes risk among the Koreans
Jee-Young Yeon, Yun Jung Bae, Eun-Young Kim, Eun-Ju Lee
Clinica Chimica Acta.2015; 439: 225. CrossRef
Association between Self-Reported Smoking and Hemoglobin A1c in a Korean Population without Diabetes: The 2011–2012 Korean National Health and Nutrition Examination Survey
Jae Won Hong, Cheol Ryong Ku, Jung Hyun Noh, Kyung Soo Ko, Byoung Doo Rhee, Dong-Jun Kim, Barbara Fuhrman
PLOS ONE.2015; 10(5): e0126746. CrossRef
Relationship between metabolic syndrome and thyroid nodules in healthy Koreans
Juyoung Shin, Min-Hee Kim, Kun-Ho Yoon, Moo-Il Kang, Bong-Yun Cha, Dong-Jun Lim
The Korean Journal of Internal Medicine.2015; 31(1): 98. CrossRef
Assessment of Cardiovascular Risk in Adults With Type 2 Diabetes and Metabolic Syndrome
Chun-Ja Kim, Hee Sun Kang, Elizabeth A. Schlenk, Sun-Mi Chae
The Diabetes Educator.2015; 41(2): 203. CrossRef
Current Status of Management in Type 2 Diabetes Mellitus at General Hospitals in South Korea
Jin-Hee Jung, Jung-Hwa Lee, Jin-Won Noh, Jeong-Eun Park, Hee-Sook Kim, Joo-Wha Yoo, Bok-Rye Song, Jeong-rim Lee, Myeong-Hee Hong, Hyang-Mi Jang, Young Na, Hyun-Joo Lee, Jeong-Mi Lee, Yang-Gyo Kang, Sun-Young Kim, Kang-Hee Sim
Diabetes & Metabolism Journal.2015; 39(4): 307. CrossRef
The number of metabolic syndrome components is a good risk indicator for both early- and late-stage kidney damage
R. Okada, Y. Yasuda, K. Tsushita, K. Wakai, N. Hamajima, S. Matsuo
Nutrition, Metabolism and Cardiovascular Diseases.2014; 24(3): 277. CrossRef
Internet-Based Mentoring Program for Patients with Type 1 Diabetes
Sun-Hye Ko, Seung-Hyun Ko
Diabetes & Metabolism Journal.2014; 38(2): 107. CrossRef
Association of Vitamin B12Deficiency and Metformin Use in Patients with Type 2 Diabetes
Sun-Hye Ko, Sun-Hee Ko, Yu-Bae Ahn, Ki-Ho Song, Kyung-Do Han, Yong-Moon Park, Seung-Hyun Ko, Hye-Soo Kim
Journal of Korean Medical Science.2014; 29(7): 965. CrossRef
Plasma Glucose Regulation and Mortality in Korea: A Pooled Analysis of Three Community-Based Cohort Studies
Nan Hee Kim, Dong-Jun Kim, Seok Won Park, Jee-Young Oh, Joong-Yeol Park, Chol Shin, Hong Kyu Lee, Yongsoo Park
Diabetes & Metabolism Journal.2014; 38(1): 44. CrossRef
The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub‐analysis from the A 1 chieve ® study
Y.‐C. Hwang, J. G. Kang, K. J. Ahn, B. S. Cha, S.‐H. Ihm, S. Lee, M. Kim, B.‐W. Lee
International Journal of Clinical Practice.2014; 68(11): 1338. CrossRef
Higher Prevalence and Awareness, but Lower Control Rate of Hypertension in Patients with Diabetes than General Population: The Fifth Korean National Health and Nutrition Examination Survey in 2011
Seung-Hyun Ko, Hyuk-Sang Kwon, Dae Jung Kim, Jae Hyeon Kim, Nan Hee Kim, Chul Sik Kim, Kee-Ho Song, Jong Chul Won, Soo Lim, Sung Hee Choi, Kyungdo Han, Yong-Moon Park, Bong-Yun Cha
Diabetes & Metabolism Journal.2014; 38(1): 51. CrossRef
Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
Cheol-Young Park, Jun Goo Kang, Suk Chon, Junghyun Noh, Seung Joon Oh, Chang Beom Lee, Sung Woo Park, T. Mark Doherty
PLoS ONE.2014; 9(3): e87799. CrossRef
Glycaemic and haemoglobin A1c thresholds for detecting diabetic retinopathy: The fifth Korea National Health and Nutrition Examination Survey (2011)
Yong-Moon Park, Seung-Hyun Ko, Jung-Min Lee, Dae-Jung Kim, Dong-Joon Kim, Kyungdo Han, Julie K. Bower, Yu-Bae Ahn
Diabetes Research and Clinical Practice.2014; 104(3): 435. CrossRef
Development of an HbA1c-Based Conversion Equation for Estimating Glycated Albumin in a Korean Population with a Wide Range of Glucose Intolerance
Chang Hee Jung, You-Cheol Hwang, Kwang Joon Kim, Bong Soo Cha, Cheol-Young Park, Won Seon Jeon, Jae Hyeon Kim, Sang-Man Jin, Sang Youl Rhee, Jeong-taek Woo, Byung-Wan Lee, Sompop Bencharit
PLoS ONE.2014; 9(4): e95729. CrossRef
Risk of suicidal ideation in diabetes varies by diabetes regimen, diabetes duration, and HbA1c level
Hoo-Yeon Lee, Myung-Il Hahm, Sang Gyu Lee
Journal of Psychosomatic Research.2014; 76(4): 275. CrossRef
Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes
Jong Dai Kim, Cheol-Young Park, Kue Jeong Ahn, Jae Hyoung Cho, Kyung Mook Choi, Jun Goo Kang, Jae Hyeon Kim, Ki Young Lee, Byung Wan Lee, Ji Oh Mok, Min Kyong Moon, Joong Yeol Park, Sung Woo Park
Atherosclerosis.2014; 234(1): 146. CrossRef
Optimal glycated albumin cutoff value to diagnose diabetes in Korean adults: A retrospective study based on the oral glucose tolerance test
You-Cheol Hwang, Chang Hee Jung, Hong-Yup Ahn, Won Seon Jeon, Sang-Man Jin, Jeong-taek Woo, Bong Soo Cha, Jae Hyeon Kim, Cheol-Young Park, Byung-Wan Lee
Clinica Chimica Acta.2014; 437: 1. CrossRef
Higher Prevalence of Metformin-Induced Vitamin B12 Deficiency in Sulfonylurea Combination Compared with Insulin Combination in Patients with Type 2 Diabetes: A Cross-Sectional Study
Donghoon Kang, Jae-Seung Yun, Sun-Hye Ko, Tae-Seok Lim, Yu-Bae Ahn, Yong-Moon Park, Seung-Hyun Ko, Yu Wang
PLoS ONE.2014; 9(10): e109878. CrossRef
The Relationship between BMI and Glycated Albumin to Glycated Hemoglobin (GA/A1c) Ratio According to Glucose Tolerance Status
Ji Hye Huh, Kwang Joon Kim, Byung-Wan Lee, Dong Wook Kim, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee, Marta Letizia Hribal
PLoS ONE.2014; 9(2): e89478. CrossRef
Prevalence of Diabetes and Prediabetes according to Fasting Plasma Glucose and HbA1c
Ja Young Jeon, Seung-Hyun Ko, Hyuk-Sang Kwon, Nan Hee Kim, Jae Hyeon Kim, Chul Sik Kim, Kee-Ho Song, Jong Chul Won, Soo Lim, Sung Hee Choi, Myoung-jin Jang, Yuna Kim, Kyungwon Oh, Dae Jung Kim, Bong-Yun Cha
Diabetes & Metabolism Journal.2013; 37(5): 349. CrossRef
Metformin Based Dual-Combination Therapies in Drug Naïve Type 2 Diabetic Patients
Dong-Lim Kim
Diabetes & Metabolism Journal.2013; 37(6): 429. CrossRef
Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
Young Ki Lee, Sun Ok Song, Kwang Joon Kim, Yongin Cho, Younjeong Choi, Yujung Yun, Byung-Wan Lee, Eun-Seok Kang, Bong Soo Cha, Hyun Chul Lee
Diabetes & Metabolism Journal.2013; 37(6): 465. CrossRef
Long-term changes of the prevalence and control rate of hypertension among Korean adults with diagnosed diabetes: 1998–2008 Korean National Health and Nutrition Examination Survey
Seung-Hyun Ko, Hyuk-Sang Kwon, Ki-Ho Song, Yu-Bae Ahn, Kun-Ho Yoon, Hyeon Woo Yim, Won-Chul Lee, Yong-Moon Park
Diabetes Research and Clinical Practice.2012; 97(1): 151. CrossRef
Smoking and Type 2 Diabetes Mellitus
Sang Ah Chang
Diabetes & Metabolism Journal.2012; 36(6): 399. CrossRef
Body Mass Index and Waist Circumference According to Glucose Tolerance Status in Korea: The 2005 Korean Health and Nutrition Examination Survey
Hye Mi Kang, Dong-Jun Kim
Journal of Korean Medical Science.2012; 27(5): 518. CrossRef
Renal Hyperfiltration in Prediabetes Confirmed by Fasting Plasma Glucose and Hemoglobin A1c
Rieko Okada, Kenji Wakai, Mariko Naito, Emi Morita, Sayo Kawai, Guang Yin, Noriyo Ozawa, Masatoshi Furuta, Erina Koyama, Rumi Tsuchiya, Noriko Kouno, Nobuyuki Hamajima
Renal Failure.2012; 34(9): 1084. CrossRef
Higher Morning to Evening Ratio in Total Dose of Twice-Daily Biphasic Insulin Analog Might Be Effective in Achieving Glucose Control in Patients with Poorly Controlled Type 2 Diabetes
Yong-Ho Lee, Byung-Wan Lee, Hea Jin Kwon, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Diabetes Technology & Therapeutics.2012; 14(6): 508. CrossRef
The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
Sun Ok Song, Kwang Joon Kim, Byung-Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Diabetes & Metabolism Journal.2012; 36(5): 371. CrossRef
Low Density Lipoprotein Cholesterol Target Goal Attainment Rate and Physician Perceptions about Target Goal Achievement in Korean Patients with Diabetes
Jenie Yoonoo Hwang, Chang Hee Jung, Woo Je Lee, Cheol Young Park, Sung Rae Kim, Kun-Ho Yoon, Moon Kyu Lee, Sung Woo Park, Joong-Yeol Park
Diabetes & Metabolism Journal.2011; 35(6): 628. CrossRef
Letter: Diabetic Polyneuropathy and Cardiovascular Complications in Type 2 Diabetic Patients (Diabetes Metab J 2011;35:390-6)
Sun-Hye Ko, Seung-Hyun Ko
Diabetes & Metabolism Journal.2011; 35(5): 558. CrossRef

Original Articles

Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration: Won Jun Kim, Cheol-Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim; Diabetes Metab J. 2011;35(3):290-297. Published online June 30, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.3.290

4,301 View
31 Download
9 Crossref

Abstract PDF PubReader

Background

To investigate the clinical results of sitagliptin (SITA) and the characteristics of the treatment failure group or of low responders to SITA.

Methods

A retrospective study of type 2 diabetic patients reviewed 99 cases, including 12 treatment failure cases, who stopped SITA because of worsening patients' condition, and 87 cases, who continued treatment over five visits (total 9.9±10.1 months) after receiving the prescription of SITA from December 2008 to June 2009. Subjects were classified as five groups administered SITA as an initial combination with metformin (MET), add-on to metformin or sulfonylurea, and switching from sulfonylurea or thiazolidinedione. The changes in HbA1c level from the first to last visit (ΔHbA1c) in treatment maintenance group were subanalyzed.

Results

The HbA1c level was significantly reduced in four groups, including initial coadministration of SITA with metformin (ΔHbA1c=-1.1%, P<0.001), add-on to MET (ΔHbA1c=-0.6%, P=0.017), add-on to sulfonylurea (ΔHbA1c=-0.5%, P<0.001), and switching from thiazolidinedione (ΔHbA1c=-0.3%, P=0.013). SITA was noninferior to sulfonlyurea (ΔHbA1c=-0.2%, P=0.63). There was no significant adverse effect. The treatment failure group had a longer diabeties duration (P=0.008), higher HbA1c (P=0.001) and fasting plasma glucose (P=0.003) compared to the maintenance group. Subanalysis on the tertiles of ΔHbA1c showed that low-response to SITA (tertile 1) was associated with a longer diabetes duration (P=0.009) and lower HbA1c (P<0.001).

Conclusion

SITA was effective and safe for use in Korean type 2 diabetic patients. However, its clinical responses and long-term benefit-harm profile is yet to be established.

Citations

Citations to this article as recorded by

Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity
Roger Yazbeck, Simone Jaenisch, Michelle Squire, Catherine A. Abbott, Emma Parkinson-Lawrence, Douglas A. Brooks, Ross N. Butler
Scientific Reports.2019;[Epub] CrossRef
Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models
Yoko Tamaki, Kunio Maema, Makoto Kakara, Masato Fukae, Ryoko Kinoshita, Yushi Kashihara, Shota Muraki, Takeshi Hirota, Ichiro Ieiri
Drug Metabolism and Pharmacokinetics.2018; 33(6): 264. CrossRef
Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
Hae Kyung Yang, Borami Kang, Seung-Hwan Lee, Hun-Sung Kim, Kun-Ho Yoon, Bong-Yun Cha, Jae-Hyoung Cho
Diabetes & Metabolism Journal.2015; 39(4): 335. CrossRef
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
Diabetes & Metabolism Journal.2015; 39(6): 489. CrossRef
Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2015;39:342-7)
Ye An Kim
Diabetes & Metabolism Journal.2015; 39(5): 444. CrossRef
Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
Endocrinology and Metabolism.2015; 30(1): 84. CrossRef
One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitazone use in Japanese patients with type 2 diabetes mellitus
Ayako Suzuki, Nakayuki Yoshimura, Yamato Mashimo, Maiko Numakura, Yuko Fujimaki, Tomomi Maeda, Toshio Ishikawa, Shin Fujimori, Kazuhiro Eto
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2013; 7(3): 143. CrossRef
Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
Tae Jung Oh, Hye Seung Jung, Jae Hyun Bae, Yeong Gi Kim, Kyeong Seon Park, Young Min Cho, Kyong Soo Park, Seong Yeon Kim
Journal of Korean Medical Science.2013; 28(6): 881. CrossRef
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
Soo Lim, Jee Hyun An, Hayley Shin, Ah Reum Khang, Yenna Lee, Hwa Young Ahn, Ji Won Yoon, Seon Mee Kang, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Hak Chul Jang
Clinical Endocrinology.2012; 77(2): 215. CrossRef

Therapeutic Target Achievement in Type 2 Diabetic Patients after Hyperglycemia, Hypertension, Dyslipidemia Management: Ah Young Kang, Su Kyung Park, So Young Park, Hye Jeong Lee, Ying Han, Sa Ra Lee, Sung Hwan Suh, Duk Kyu Kim, Mi Kyoung Park; Diabetes Metab J. 2011;35(3):264-272. Published online June 30, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.3.264

10,052 View
35 Download
12 Crossref

Abstract PDF PubReader

Background

Our study group established "3H care" in 2002. The meaning of "3H care" attain and maintain adequate controls over hypertension, hyperlipidemia, and hyperglycemia in type 2 diabetic patients. This study evaluated the achievement of target goals after one year or more of "3H care" by specialists in our diabetic clinic.

Methods

This was a retrospective study of 200 type 2 diabetic patients who received "3H care" for one year or more in our diabetic clinic. We evaluated achievement of target goals for metabolic controls as suggested by the American Diabetes Association.

Results

Overall, 200 type 2 diabetes patients were enrolled, of whom 106 were males (53%) and 94 were females (47%). After one year of "3H care," the mean HbA1c was 7.2±1.5% and the percentage of patients achieving glycemic control (HbA1c <7%) was 51.8%. However only 32.2% of hypertensive patients achieved the recommended target. After one year of "3H care," the percentages of those who achieved the target value for dyslipidemia were 80.0% for total cholesterol, 66.3% for low density lipoprotein cholesterol, 57.9% for triglyceride, and 51.8% for high density lipoprotein cholesterol. The percentage that achieved all three targets level was only 4.4% after one year and 14.8% after two years.

Conclusion

The results of this study demonstrate that only a minor proportion of patients with type 2 diabetes achieved the recommended goals despite the implementation of "3H care." It is our suggestion that better treatment strategies and methods should be used to control hypertension, hyperlipidemia and hyperglycemia.

Citations

Citations to this article as recorded by

Achievement of the ABC goal among Canadians with type 2 diabetes and the influence of physical activity: data from the Canadian Health Measures Survey
Alexis Marcotte-Chénard, René Maréchal, Ahmed Ghachem, Alan Cohen, Eléonor Riesco
Applied Physiology, Nutrition, and Metabolism.2023; 48(9): 657. CrossRef
Poor Adherence to Common Recommendations and Associated Factors among Outpatients with Type 2 Diabetes Mellitus in a Police Hospital of Ethiopia
Tariku Shimels, Melesse Abebaw, Gebremedhin Beedemariam Gebretekle
Journal of Social Health and Diabetes.2021; 9(01): e8. CrossRef
Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period
Abbas Ali Mansour, Nassar T.Y. Alibrahim, Haider A. Alidrisi, Ali H. Alhamza, Ammar M. Almomin, Ibrahim Abbood Zaboon, Muayad Baheer Kadhim, Rudha Naser Hussein, Hussein Ali Nwayyir, Adel Gassab Mohammed, Dheyaa K.J. Al-Waeli, Ibrahim Hani Hussein
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(3): 265. CrossRef
Notoginsenoside R1 Ameliorates Diabetic Retinopathy through PINK1-Dependent Activation of Mitophagy
Ping Zhou, Weijie Xie, Xiangbao Meng, Yadong Zhai, Xi Dong, Xuelian Zhang, Guibo Sun, Xiaobo Sun
Cells.2019; 8(3): 213. CrossRef
Association of Self-Reported Dietary and Drug Compliance with Optimal Metabolic Control in Patients with Type 2 Diabetes: Clinic-Based Single-Center Study in a Developing Country
Thilak Priyantha Weerarathna, Miyuru Kavinda Weerarathna, Vidarsha Senadheera, Herath Mudiyanselage Meththananda Herath, Gayani Liyanage
Journal of Nutrition and Metabolism.2018; 2018: 1. CrossRef
Prevalence of primary aldosteronism among patients with type 2 diabetes
Mauro Tancredi, Gudmundur Johannsson, Björn Eliasson, Robert Eggertsen, Ulf Lindblad, Sofia Dahlqvist, Henrik Imberg, Marcus Lind
Clinical Endocrinology.2017; 87(3): 233. CrossRef
GS-E3D, a new pectin lyase-modified red ginseng extract, inhibited diabetes-related renal dysfunction in streptozotocin-induced diabetic rats
Chan-Sik Kim, Kyuhyung Jo, Jin Sook Kim, Mi-Kyung Pyo, Junghyun Kim
BMC Complementary and Alternative Medicine.2017;[Epub] CrossRef
Ursodeoxycholic acid and 4-phenylbutyrate prevent endoplasmic reticulum stress-induced podocyte apoptosis in diabetic nephropathy
Ai-Li Cao, Li Wang, Xia Chen, Yun-Man Wang, Heng-Jiang Guo, Shuang Chu, Cheng Liu, Xue-Mei Zhang, Wen Peng
Laboratory Investigation.2016; 96(6): 610. CrossRef
Ursodeoxycholic Acid Ameliorated Diabetic Nephropathy by Attenuating Hyperglycemia-Mediated Oxidative Stress
Aili Cao, Li Wang, Xia Chen, Hengjiang Guo, Shuang Chu, Xuemei Zhang, Wen Peng
Biological & Pharmaceutical Bulletin.2016; 39(8): 1300. CrossRef
Withania coagulansFruit Extract Reduces Oxidative Stress and Inflammation in Kidneys of Streptozotocin-Induced Diabetic Rats
Shreesh Ojha, Juma Alkaabi, Naheed Amir, Azimullah Sheikh, Ahmad Agil, Mohamed Abdelmonem Fahim, Abdu Adem
Oxidative Medicine and Cellular Longevity.2014; 2014: 1. CrossRef
Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA
J. Smith, J.‐A. Nazare, A.‐L. Borel, P. Aschner, P. J. Barter, L. Van Gaal, Y. Matsuzawa, T. Kadowaki, R. Ross, C. Brulle‐Wohlhueter, N. Alméras, S. M. Haffner, B. Balkau, J.‐P. Després
Diabetes, Obesity and Metabolism.2013; 15(7): 629. CrossRef
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
Pitchai Balakumar, Supriya Kadian, Nanjaian Mahadevan
Pharmacological Research.2012; 65(4): 430. CrossRef

The Current Status of Type 2 Diabetes Management at a University Hospital.: Young Sil Lee; Korean Diabetes J. 2009;33(3):241-250. Published online June 1, 2009; DOI: https://doi.org/10.4093/kdj.2009.33.3.241

2,230 View
22 Download
10 Crossref

Abstract PDF

BACKGROUND
The prevalence of type 2 diabetes has increased worldwide, as have the incidence and mortality of associated cardiovascular complication. However current status of diabetes management is poor. This study was performed to evaluate the management of care for type 2 diabetes patients at a university hospital. METHODS: This study comprised 926 type 2 diabetes patients, over the age of 30, who were treated at the Dongguk University Gyeongju Hospital between January and December 2008. Medical records were reviewed to collect demographic information, biochemical test results and the pharmacologic agents prescribed. RESULTS: The mean age, duration of diabetes and body mass index were 62.5 +/- 11.8 years, 9.1 +/- 7.2 year and 24.7 +/- 6.3 kg/m2, respectively. There were 251/926 (27.1%) patients with cardiovascular disease. In addition, 49.2% and 27.5% of patients had HbA1c levels < 7% and < 6.5%, respectively. There were 66.3% of the patients with blood pressure < 130/80 mm Hg. Fifty one percent and 47.4% of the patients had an LDL-C < 100 mg/dL and a non-HDL-C < 130 mg/dL, respectively. In addition, 19.7% of the patients with cardiovascular disease had an LDL-C < 70 mg/dL. Antiplatelet agents were used in 81.2% of the patients. The mean number of HbA1c measurements was 1.07 +/- 0.7 /year. HbA1c and lipid profiles were not checked in 21.4% and 23.1% of the patients, respectively. Over the previous six months, 6.9% of the patients had not had their blood pressure monitored. CONCLUSION: Among the patients with type 2 diabetes evaluated, 30~70% received in inadequate level of care. These findings point to the need for more aggressive efforts for optimal metabolic control.

Citations

Citations to this article as recorded by

Developing a nomogram for predicting depression in diabetic patients after COVID-19 using machine learning
Haewon Byeon
Frontiers in Public Health.2023;[Epub] CrossRef
Factors Influencing the Utilization of Diabetes Complication Tests Under the COVID-19 Pandemic: Machine Learning Approach
Haewon Byeon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Correlation between the Activity of Aldehyde Dehydrogenase and Oxidative Stress Markers in the Saliva of Diabetic Patients
Hina Younus, Sumbul Ahmad, Md. Fazle Alam
Protein & Peptide Letters.2019; 27(1): 67. CrossRef
Current status of treatment of type 2 diabetes mellitus in Ningbo, China
Tianmeng Yang, Rongjiong Zheng, Qingmei Chen, Yushan Mao
Journal of Clinical Laboratory Analysis.2019;[Epub] CrossRef
Current Status of Management in Type 2 Diabetes Mellitus at General Hospitals in South Korea
Jin-Hee Jung, Jung-Hwa Lee, Jin-Won Noh, Jeong-Eun Park, Hee-Sook Kim, Joo-Wha Yoo, Bok-Rye Song, Jeong-rim Lee, Myeong-Hee Hong, Hyang-Mi Jang, Young Na, Hyun-Joo Lee, Jeong-Mi Lee, Yang-Gyo Kang, Sun-Young Kim, Kang-Hee Sim
Diabetes & Metabolism Journal.2015; 39(4): 307. CrossRef
Glucose, Blood Pressure, and Lipid Control in Korean Adults with Diagnosed Diabetes
Sun-Joo Boo
Korean Journal of Adult Nursing.2012; 24(4): 406. CrossRef
Diabetics' Preference in the Design Factors and Performance Requirements of Diabetic Socks
Ji-Eun Lee, Young-Ah Kwon
Journal of the Korean Society of Clothing and Textiles.2011; 35(5): 527. CrossRef
Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types
Mi-Ju Choi, Seung-Hyun Yoo, Kum-Rae Kim, Yoo-Mi Bae, Sun-Hee Ahn, Seong-Shin Kim, Seong-Ah Min, Jin-Sun Choi, Seung-Eun Lee, Yeo-Jin Moon, Eun Jung Rhee, Cheol-Young Park, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim
Diabetes & Metabolism Journal.2011; 35(6): 580. CrossRef
Therapeutic Target Achievement in Type 2 Diabetic Patients after Hyperglycemia, Hypertension, Dyslipidemia Management
Ah Young Kang, Su Kyung Park, So Young Park, Hye Jeong Lee, Ying Han, Sa Ra Lee, Sung Hwan Suh, Duk Kyu Kim, Mi Kyoung Park
Diabetes & Metabolism Journal.2011; 35(3): 264. CrossRef
A Predictive Model on Self Care Behavior for Patients with Type 2 Diabetes: Based on Self-Determination Theory
Yeong Mi Seo, Won Hee Choi
Journal of Korean Academy of Nursing.2011; 41(4): 491. CrossRef

Clinical Characteristics of Non-obese, Adult-onset Diabetes Requiring Insulin Treatment.: Se Eun Park, Wan Sub Shim, Mi Young Do, Eun Seok Kang, Yumie Rhee, Chul Woo Ahn, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee, Bong Soo Cha; Korean Diabetes J. 2005;29(6):557-565. Published online November 1, 2005

1,079 View
16 Download

Abstract PDF: BACKGROUND
The aim of this study is to clarify the clinical characteristics of non-obese, adult-onset diabetes requiring insulin treatment and to compare the different characteristics of the three groups categorized according to diabetes classification. METHODS: Total 128 diabetic patients who were non-obese (BMI < 25kg/m2) and had been diagnosed with diabetes after 20 years old, requiring insulin treatment were enrolled in the study. We divided the patients into three groups : 56 patients with type 1, 37 with unclassifiable, and 35 with type 2 diabetes. The type of diabetes was assigned by comparing serum C-peptide concentration and clinical phenotypes. RESULTS: Type 2 and unclassifiable diabetes had no differences in BMI, the interval to use insulin, daily insulin dose, the level of HDL cholesterol and the positive rate for GAD Ab, but type 1 diabetes didn't. However, type 1 diabetes and unclassifiable group was lower prevalence of microvascular complications than type 2 diabetes (retinopathy 38.2, 52.8, 84.8 % ; nephropathy 37.7, 36.7, 74.2 % ; neuropathy 36.7, 36.7, 72.7 %, P<0.05). The prevalence of macrovascular complications was higher in the order of type 1, unclassifiable, and type 2 diabetes (11.1, 29.4, 72.7 %, respectively, all P<0.05). CONCLUSION: The clinical characteristics were similar between unclassifiable and type 2 diabetes, but the prevalence of microvascular complication in unclassifiable group had no significant difference compared with type 1 diabetes. The prevalence of macrovascular complications was significantly higher in the order of type 1, unclassifiable, and type 2 diabetes.

First
Prev
Page of 2
Next
Last

Search